[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 129
1. Ikenaga N, Yamaguchi K, Konomi H, Fujii K, Sugitani A, Tanaka M: A minute nonfunctioning islet cell tumor demonstrating malignant features. J Hepatobiliary Pancreat Surg; 2005;12(1):84-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A minute nonfunctioning islet cell tumor demonstrating malignant features.
  • We report a patient with a minute nonfunctioning islet cell tumor, 8 mm in diameter, which demonstrated malignant features by histology.
  • Ultrasonography and computed tomography demonstrated a well-defined pancreatic tumor, 8 mm in diameter, in the body of the pancreas.
  • Serum levels of pancreatic hormones were within normal limits, and thus a tentative diagnosis was nonfunctioning islet cell tumor.
  • The size of the tumor remained unchanged for 1 1/2 years, but, at this time, the serum level of CA19-9 was elevated to 253 U/ml.
  • The resected specimen showed an endocrine tumor invading both the pancreatic parenchyma and the perineural spaces outside the tumor.
  • In general, minute nonfunctioning islet cell tumors have been considered to be completely benign, but the present tumor showed clear malignant features.
  • We might have to take surgical resection into consideration even if the size of such an endocrine tumor is minute.
  • [MeSH-major] Adenoma, Islet Cell / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754106.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Paik WH, Yoon YB, Lee SH, Park JK, Woo SM, Yang KY, Seo JK, Ryu JK, Kim YT: [Pancreatic endocrine tumors: clinical manifestations and predictive factors associated with survival]. Korean J Gastroenterol; 2008 Sep;52(3):171-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic endocrine tumors: clinical manifestations and predictive factors associated with survival].
  • BACKGROUND/AIMS: Since pancreatic endocrine tumors (PET) are rare and heterogeneous diseases, their survival and prognosis are not well known.
  • However, tumor size and pathology showed no significant association with survival.
  • CONCLUSIONS: Because small and pathologically benign nature do not predict good prognosis in PET, aggressive treatment such as curative resection would be considered initially even in the case of incidental PET.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / mortality. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077513.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Jackson C, Buchman AL: Calcitonin-secreting VIPoma. Dig Dis Sci; 2005 Dec;50(12):2203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Calcitonin / biosynthesis. Vipoma / pathology
  • [MeSH-minor] Biopsy, Needle. Chronic Disease. Diarrhea / diagnosis. Diarrhea / etiology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laparoscopy / methods. Middle Aged. Pancreatectomy / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Rare Diseases. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - VIPoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416161.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-12-9 / Calcitonin
  •  go-up   go-down


Advertisement
4. Chun MG, Mao JH, Chiu CW, Balmain A, Hanahan D: Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proc Natl Acad Sci U S A; 2010 Oct 5;107(40):17268-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis.
  • Cancer is a disease subject to both genetic and environmental influences.
  • In this study, we used the RIP1-Tag2 (RT2) mouse model of islet cell carcinogenesis to identify a genetic locus that influences tumor progression to an invasive growth state.
  • RT2 mice inbred into the C57BL/6 (B6) background develop both noninvasive pancreatic neuroendocrine tumors (PNET) and invasive carcinomas with varying degrees of aggressiveness.
  • A gene residing in this locus, the anaplastic lymphoma kinase (Alk), was expressed at significantly lower levels in PNETs from invasion-resistant C3H mice compared with invasion-susceptible B6 mice, and pharmacological inhibition of Alk led to reduced tumor invasiveness in RT2 B6 mice.
  • Collectively, our results demonstrate that tumor invasion is subject to polymorphic genetic control and identify Alk as a genetic modifier of invasive tumor growth.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2000 Dec 15;352 Pt 3:601-10 [11104663.001]
  • [Cites] PLoS Genet. 2010 Sep;6(9):e1001120 [20862307.001]
  • [Cites] Cancer Cell. 2002 May;1(4):339-53 [12086849.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:238-44 [12610533.001]
  • [Cites] Nat Rev Genet. 2003 Sep;4(9):721-34 [12951573.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2406-10 [15059892.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Carcinogenesis. 1993 Nov;14(11):2353-8 [8242866.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Nat Genet. 1995 Aug;10(4):424-9 [7670492.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):241-7 [7581446.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Nature. 1998 Mar 12;392(6672):190-3 [9515965.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):640-4 [9679770.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18147-52 [15608061.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):243-53 [15711544.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4037-51 [15806157.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1055-62 [16142231.001]
  • [Cites] Blood. 2006 Jan 15;107(2):689-97 [16189272.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):543-56 [16481467.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):761-5 [17230190.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Nat Genet. 2008 May;40(5):623-30 [18372905.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3591-600 [18483240.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Sep;13(3):337-42 [18661105.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Nature. 2009 Mar 26;458(7237):505-8 [19136944.001]
  • [Cites] Oncogene. 2009 Sep 17;28(37):3296-306 [19633684.001]
  • [Cites] Breast Cancer Res. 2009;11(5):R75 [19825179.001]
  • [Cites] Genes Dev. 2010 Feb 1;24(3):241-55 [20080943.001]
  • [Cites] Mol Cancer. 2010;9:51 [20205715.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2603-13 [19847808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8 [20457905.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):459-64 [11694878.001]
  • (PMID = 20855625.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R01CA45234-24; United States / NCI NIH HHS / CA / U01-CA84244; United States / NICHD NIH HHS / HD / U01 HD043430; United States / NCI NIH HHS / CA / R01 CA045234; United States / NICHD NIH HHS / HD / U01-HD43430; United States / NCI NIH HHS / CA / U01 CA084244
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NVP-TAE684; 0 / Pyrimidines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2951397
  •  go-up   go-down


5. Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep; 2009 Apr;11(2):119-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic endocrine tumors are rare neoplasms accounting for less than 5% of pancreatic malignancies.
  • Signs and symptoms are usually related to hormone hypersecretion in the case of functioning tumors and to tumor size or metastases with nonfunctioning tumors.
  • Surgical resection remains the treatment of choice even in the face of metastatic disease.
  • Further development of novel diagnostic and treatment modalities offers potential to greatly improve quality of life and prolong disease-free survival for patients with pancreatic endocrine tumors.
  • [MeSH-major] Adenoma, Islet Cell. Carcinoma, Islet Cell. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1329-34 [1678681.001]
  • [Cites] World J Surg. 2008 May;32(5):904-17 [18264824.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:182-4 [10436817.001]
  • [Cites] J Gastroenterol. 2007 Jun;42(6):497-500 [17671766.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):138-45 [16368504.001]
  • [Cites] Gastroenterology. 1968 Dec;55(6):677-86 [4302500.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):410-9 [16926567.001]
  • [Cites] Arch Surg. 1984 May;119(5):508-14 [6143548.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):409-27 [18508996.001]
  • [Cites] Eur J Surg Oncol. 2008 Mar;34(3):324-32 [17967523.001]
  • [Cites] Am J Med. 1999 Mar;106(3):307-10 [10190379.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3532-7 [18825460.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):987-92 [14500214.001]
  • [Cites] Dig Dis Sci. 1991 Jul;36(7):933-42 [2070707.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1721-6 [1317506.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17 (4):427-32 [8362525.001]
  • [Cites] Transplantation. 1998 Nov 27;66(10):1307-12 [9846513.001]
  • [Cites] Medicine (Baltimore). 1996 Mar;75(2):53-63 [8606627.001]
  • [Cites] Curr Probl Surg. 1990 Jun;27(6):301-86 [1973365.001]
  • [Cites] N Engl J Med. 1977 Apr 28;296(17):963-7 [321960.001]
  • [Cites] Mayo Clin Proc. 1991 Jul;66(7):711-9 [1677058.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):165-72 [18156937.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Ann Surg. 1955 Oct;142(4):709-23; discussion, 724-8 [13259432.001]
  • [Cites] N Engl J Med. 1986 May 1;314(18):1145-51 [3007986.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):249-53 [11314942.001]
  • [Cites] Am J Med. 1958 Sep;25(3):374-80 [13571250.001]
  • [Cites] Surg Clin North Am. 1987 Apr;67(2):379-93 [3031836.001]
  • [Cites] Curr Opin Oncol. 1999 Jan;11(1):32-7 [9914875.001]
  • [Cites] Pathol Res Pract. 1988 Apr;183(2):155-68 [2898775.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2622-8 [9253344.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):473-82 [18335273.001]
  • [Cites] Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70 [16924083.001]
  • [Cites] J Med Res. 1902 Nov;8(2):385-95 [19971505.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5609-15 [18065733.001]
  • [Cites] Radiology. 1993 Mar;186(3):799-802 [8381551.001]
  • [Cites] Am J Surg. 1990 Feb;159(2):258-64 [2154144.001]
  • (PMID = 19281699.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins; 0 / Insulin; 51110-01-1 / Somatostatin; 9007-92-5 / Glucagon
  • [Number-of-references] 44
  •  go-up   go-down


6. Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB: Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol; 2007 May;188(5):1201-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Forty-six patients with carcinoid (n = 31) or islet cell (n = 15) tumors were treated.
  • Potential factors affecting survival, including presence of extrahepatic disease and resection of the primary lesion, were analyzed.
  • The mean overall survival times for the carcinoid (1,255 +/- 163 days) and islet cell tumor (1,311 +/- 403 days) subgroups were similar (p = 0.66).
  • The progression-free survival times for the carcinoid (602 +/- 144 days) and islet cell (501 +/- 107 days) tumor subgroups also were similar (p = 0.72).
  • The survival time of patients without known extrahepatic metastasis (n = 18; 1,571 +/- 291 days) trended toward significance compared with that of patients with known extrahepatic disease (n = 26; 770 +/- 112 days; p = 0.08).
  • Resection of the primary tumor in 19 of 46 patients did not affect survival (resection survival, 1,558 +/- 400 days; nonresection survival, 1,000 +/- 179 days; p = 0.44).
  • The presence of extrahepatic metastasis or an unresected primary tumor should not limit the use of hepatic artery chemoembolization or HAE.
  • [MeSH-minor] Adenoma, Islet Cell / therapy. Adult. Aged. Carcinoid Tumor / secondary. Carcinoid Tumor / therapy. Embolization, Therapeutic. Female. Hepatic Artery. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449759.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. de Sá SV, Corrêa-Giannella ML, Machado MC, de Souza JJ, Pereira MA, Patzina RA, Siqueira SA, Machado MC, Giannella-Neto D: Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer; 2006 Mar;13(1):69-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.
  • Insulinomas are rare endocrine neoplasias that constitute the most frequent islet cell tumours.
  • Somatostatin (SST) analogs are tentatively used to inhibit insulin secretion and control tumour growth in patients with local invasion or inoperative metastasis, but variable responses have been reported.
  • Histopathological and immunohistochemical analysis for some features associated with tumour aggressiveness and semi-quantitative RT-PCR for SSTR1-5 and real-time qPCR for SSTR5 were performed.
  • SSTR5 mRNA was positively correlated with histopathological features related to tumour aggressiveness (large tumour diameter, well-differentiated endocrine tumour with uncertain behaviour and higher number of cells with nuclear atypia).
  • The observed positive correlation between SSTR5 expression and tumour size suggests that the use of SST analogues more specific to SSTR5 in the treatment of insulinomas deserves attention.
  • [MeSH-major] Cell Proliferation. Insulinoma / pathology. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Receptors, Somatostatin / genetics
  • [MeSH-minor] Adenoma, Islet Cell. Adolescent. Adult. Aged. Female. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Pituitary Hormones / metabolism. Pituitary Neoplasms / genetics. Pituitary Neoplasms / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16601280.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pituitary Hormones; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 5
  •  go-up   go-down


8. Choi H, Kim S, Moon JH, Lee YH, Rhee Y, Kang ES, Ahn CW, Cha BS, Lee EJ, Kim KR, Lee HC, Jeong SY, Kim HJ, Lim SK: Multiple endocrine neoplasia type 1 with multiple leiomyomas linked to a novel mutation in the MEN1 gene. Yonsei Med J; 2008 Aug 30;49(4):655-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple endocrine neoplasia type 1 with multiple leiomyomas linked to a novel mutation in the MEN1 gene.
  • Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited syndrome.
  • MEN1 is characterized by the presence of functioning and nonfunctioning tumors or hyperplasia of the pituitary gland, parathyroid glands, and pancreatic islet cells.
  • In addition, MEN1 carriers can have adrenal or thyroid tumors and non-endocrine tumors, such as lipomas, angiofibromas, and leiomyomas.
  • Endoscopic ultrasonography demonstrated esophageal leiomyoma and pancreatic islet cell tumor.
  • This is the first case of MEN1 accompanied with multiple leiomyomas, parathyroid adenoma, pituitary adenoma, pancreatic tumor, and adrenal tumor.
  • [MeSH-major] Leiomyomatosis / metabolism. Leiomyomatosis / pathology. Multiple Endocrine Neoplasia Type 1 / metabolism


9. Toxicology and carcinogenesis studies of androstenedione (CAS No. 63-05-8) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser; 2010 Sep;(560):1, 7-31,33-171 passim
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of mononuclear cell leukemia were significantly increased in 20 and 50 mg/kg females and significantly decreased in 20 and 50 mg/kg males.
  • Incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined) were significantly increased in 20 mg/kg males.
  • The incidence of testicular interstitial cell adenoma (including bilateral) was significantly decreased in 50 mg/kg males.
  • In the liver of males, the incidences of basophilic focus in all dosed groups, the incidence of clear cell focus in the 20 mg/kg group, and the incidence of eosinophilic focus in the 50 mg/kg group were significantly increased.
  • The incidences of pancreatic islet hyperplasia and atrophy of the exocrine pancreas were significantly increased in 50 mg/kg females.
  • The incidences of hepatocellular adenoma in males and females were significantly increased in the 50 mg/kg groups.
  • Incidences of hepatocellular adenoma or carcinoma (combined) in males and females were significantly increased in the 50 mg/kg groups.
  • Incidences of multiple hepatocellular adenomas and carcinomas were significantly increased in 10 and 50 mg/kg males, and there was an increased incidence of multiple hepatocellular adenomas in 50 mg/kg females.
  • The incidence of eosinophilic focus was significantly increased in 50 mg/kg males, and the incidences of mixed cell focus and cytoplasmic vacuolization were significantly increased in 50 mg/kg females.
  • There was a marginally increased incidence of pancreatic islet adenoma in 50 mg/kg males and in 10 and 50 mg/kg females, with an earlier day of first incidence in males.
  • CONCLUSIONS: under the conditions of these 2-year gavage studies, there was equivocal evidence of carcinogenic activity of androstenedione in male F344/N rats based on increased incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined).
  • There was equivocal evidence of carcinogenic activity of androstenedione in female F344/N rats based on increased incidences of mononuclear cell leukemia.
  • There was clear evidence of carcinogenic activity of androstenedione in male B6C3F1 mice based on increased incidences of multiple hepatocellular adenoma and hepatocellular carcinoma and increased incidence of hepatoblastoma.
  • There was clear evidence of carcinogenic activity of androstenedione in female B6C3F1 mice based on increased incidences of hepatocellular adenoma and hepatocellular carcinoma.
  • Increased incidences of pancreatic islet adenoma in male and female mice were also considered chemical related.
  • Androstenedione administration caused increased incidences in nonneoplastic lesions of the liver in male and female rats and mice; pancreatic islets and exocrine pancreas of female rats; and clitoral gland, kidney, and submandibular salivary gland of female mice.
  • Decreases in the incidences of testicular interstitial cell adenoma in male rats, mammary gland fibroadenoma, cysts, and hyperplasia in female rats, and malignant lymphoma in female mice were considered related to androstenedione administration.

  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21037592.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Review; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Mutagens; 409J2J96VR / Androstenedione
  •  go-up   go-down


10. Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L: Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology; 2007;85(4):216-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy.
  • BACKGROUND/AIMS: The use of chemoradiation in the management of locally advanced pancreatic endocrine tumors has not been reported in the medical literature.
  • Given the sensitivity of pancreatic endocrine tumors to cytotoxic agents including streptozocin, doxorubicin and 5-FU, we have hypothesized that the combination of concurrent and sequential chemotherapy and radiation will yield higher response rates than acheivable with chemotherapy alone.
  • METHODS: Six patients with locally advanced pancreatic endocrine tumors were treated with a protocol consisting of radiation concurrent with infusional 5-FU (or capecitabine) along with induction and consolidation chemotherapy (streptozocin and doxorubicin).
  • With a median follow-up of 29 months, all six patients in the study have had continued reduction in tumor size from the time of the first posttreatment scan to the most recent scan.
  • None of the patients have experienced local or metastatic disease progression.
  • CONCLUSION: The combination of concurrent and sequential chemoradiotherapy appears to be a highly effective treatment for locally advanced pancreatic endocrine tumors.
  • [MeSH-major] Adenoma, Islet Cell / drug therapy. Adenoma, Islet Cell / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17541257.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5W494URQ81 / Streptozocin; 6804DJ8Z9U / Capecitabine; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Kim DH, Nagano Y, Choi IS, White JA, Yao JC, Rashid A: Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer; 2008 Jan;47(1):84-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors.
  • We used genome-wide high-density single nucleotide polymorphism (SNP) array analysis to detect copy number alterations in 29 WDNTs, including seven lung, seven nonileal gastrointestinal, and 15 ileal tumors, and compared with allelic imbalances in 15 pancreatic endocrine tumors (PETs).
  • We also found one tumor with loss of heterozygosity of chromosomes 10 and 15 without copy number loss.
  • These allelic imbalances were associated with primary site of tumor: loss of chromosome 18 was present exclusively in ileal WDNTs (P = 0.001), and loss of chromosome 21 or 21q was more frequent in nonileal gastrointestinal WDNTs (P = 0.02).
  • Our study shows that genome-wide allelotyping using SNP array is a powerful new tool for the analysis of allelic imbalances in WDNTs, and some of these alterations are tumor site-dependent and are different than in PETs.
  • [MeSH-major] Adenoma, Islet Cell / genetics. Allelic Imbalance. Carcinoid Tumor / genetics. Cell Differentiation / genetics. Genome, Human. Polymorphism, Single Nucleotide

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943967.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Jiang KR, Miao Y, Xu ZK, Qian ZY, Dai CC, Xie L, Wu JL, Li Q, Xi CH, Guo F, Chen JM, Gao WT, Liu XL: [Diagnosis and surgical treatment for non-functional islet cell tumor: a retrospective analysis of 44 cases]. Zhonghua Wai Ke Za Zhi; 2009 Mar 1;47(5):326-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment for non-functional islet cell tumor: a retrospective analysis of 44 cases].
  • OBJECTIVE: To evaluate the methods of diagnosis and surgical treatment for nonfunctional islet cell tumor (NICT).
  • METHODS: Forty-four patients with non-functional islet cell tumor treated at the First Affiliated Hospital of Nanjing Medical University during January 1968 to June 2008 were analyzed retrospectively.
  • Clinical manifestation: 15 cases (34.1%) of abdominal masses, 17 patients (38.6%) with epigastric or back pain, 5 cases of jaundice, 5 cases (11.4%) for upper abdominal fullness or vomiting, 10 cases (22.7%) of pancreatic tumor noticed by routine health checkups or imaging examinations.
  • RESULTS: pancreatic fistula in 7 patients (15.9%), intra-abdominal bleeding in 4 (9.1%), gastrojejunal anastomosis outlet obstruction in 1 (2.3%), biliary fistula in 2 (4.5%) and incisional infection in 3 (6.8%).
  • CONCLUSIONS: No specific clinical manifestation is recognized for non-functional islet cell tumor.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / surgery. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595003.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Ekeblad S, Lejonklou MH, Grimfjärd P, Johansson T, Eriksson B, Grimelius L, Stridsberg M, Stålberg P, Skogseid B: Co-expression of ghrelin and its receptor in pancreatic endocrine tumours. Clin Endocrinol (Oxf); 2007 Jan;66(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of ghrelin and its receptor in pancreatic endocrine tumours.
  • OBJECTIVE: Expression of ghrelin has been reported in pancreatic endocrine tumours, but data on ghrelin receptor protein expression are lacking.
  • The aim of this study was to examine the ghrelin receptor, as well as ghrelin, in a selected series of these tumours, including multiple endocrine neoplasia 1 (MEN1) associated tumours, and to correlate data with clinical features including body mass index.
  • CONCLUSIONS: We report the first immunohistochemical data on expression of the ghrelin receptor in pancreatic endocrine tumours: 70% of tumours in our material.
  • [MeSH-major] Adenoma, Islet Cell / metabolism. Pancreatic Neoplasms / metabolism. Peptide Hormones / genetics. Receptors, G-Protein-Coupled / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Body Mass Index. Chi-Square Distribution. Female. Gene Expression. Ghrelin. Humans. Immunohistochemistry. Insulinoma / chemistry. Insulinoma / metabolism. Male. Middle Aged. Multiple Endocrine Neoplasia Type 1 / chemistry. Multiple Endocrine Neoplasia Type 1 / metabolism. Receptors, Ghrelin. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201810.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Peptide Hormones; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Ghrelin
  •  go-up   go-down


14. Abe H, Murakami T, Kubota M, Kim T, Hori M, Kudo M, Hashimoto K, Nakamori S, Dono K, Tomoda K, Monden M, Nakamura H: Quantitative tissue blood flow evaluation of pancreatic tumor: comparison between xenon CT technique and perfusion CT technique based on deconvolution analysis. Radiat Med; 2005 Aug;23(5):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative tissue blood flow evaluation of pancreatic tumor: comparison between xenon CT technique and perfusion CT technique based on deconvolution analysis.
  • PURPOSE: There has been one report that tissue blood flow (TBF) quantification with xenon CT was effective in predicting the therapeutic response to an anticancer drug in pancreatic cancer.
  • The purpose of this study was to evaluate the correlation between the TBF of pancreatic tumors calculated with xenon CT and those with perfusion CT, in order to evaluate whether perfusion CT could replace xenon CT.
  • MATERIALS AND METHODS: Nine patients with pathologically proved pancreatic tumors who underwent both xenon CT and perfusion CT were included.
  • RESULTS: Quantitative TBF of pancreatic tumors measured by perfusion CT ranged from 22.1 to 196.2 ml/min/100 g (mean+/-SD, 52.6+/-54.8 ml/min/100 g).
  • CONCLUSION: The TBF of pancreatic tumors measured by xenon CT and perfusion CT techniques showed a close linear correlation.
  • We can expect that perfusion CT based on the deconvolution algorithm may replace xenon CT to predict the effect of pancreatic tumor treatment with anticancer drugs.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenoma, Islet Cell / blood supply. Contrast Media / administration & dosage. Pancreatic Neoplasms / blood supply. Tomography, Spiral Computed / methods. Tomography, X-Ray Computed / methods. Xenon / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342909.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; 3H3U766W84 / Xenon
  •  go-up   go-down


15. Yao VJ, Ozawa MG, Varner AS, Kasman IM, Chanthery YH, Pasqualini R, Arap W, McDonald DM: Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res; 2006 Mar 01;66(5):2639-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels.
  • Tumor blood vessels normalized by antiangiogenic therapy may provide improved delivery of chemotherapeutic agents during a window of time but it is unknown how protein expression in tumor vascular endothelial cells changes.
  • We evaluated the distribution of RGD-4C phage, which binds alpha(v)beta(3), alpha(v)beta(5), and alpha(5)beta(1) integrins on tumor blood vessels before and after antiangiogenic therapy.
  • Cellular distribution of RGD-4C phage in surviving tumor vessels matched the alpha(5)beta(1) integrin expression.
  • The reduction in integrin expression on tumor vessels after antiangiogenic therapy raises the possibility that integrin-targeted delivery of diagnostics or therapeutics may be compromised.
  • Efficacious delivery of drugs may benefit from identification by in vivo phage display of targeting peptides that bind to tumor blood vessels normalized by antiangiogenic agents.
  • [MeSH-major] Adenoma, Islet Cell / blood supply. Bacteriophage M13 / metabolism. Endothelial Cells / virology. Imidazoles / pharmacology. Indazoles / pharmacology. Integrin alpha5beta1 / biosynthesis. Integrin alphaVbeta3 / biosynthesis. Pancreatic Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510583.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-24136; United States / NHLBI NIH HHS / HL / P01 HL024136; United States / NCI NIH HHS / CA / P50-CA90270; United States / NCI NIH HHS / CA / CA88106; United States / NCI NIH HHS / CA / CA90810; United States / NHLBI NIH HHS / HL / HL-59157
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Indazoles; 0 / Integrin alpha5beta1; 0 / Integrin alphaVbeta3; 0 / Oligopeptides; 78VO7F77PN / arginyl-glycyl-aspartic acid; C9LVQ0YUXG / axitinib
  •  go-up   go-down


16. Mascarenhas NB, Mulcahy MF, Lewandowski RJ, Salem R, Ryu RK: Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. Cardiovasc Intervent Radiol; 2010 Jun;33(3):650-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Embolization, Therapeutic / adverse effects. Liver Abscess / etiology. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688373.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


17. Hamzah J, Nelson D, Moldenhauer G, Arnold B, Hämmerling GJ, Ganss R: Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest; 2008 May;118(5):1691-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we used a tumor-homing peptide to engineer anti-CD40 agonist antibodies and recombinant IL-2 such that they were selectively delivered into spontaneously arising tumors in a transgenic mouse model of islet cell carcinogenesis.
  • Intravenous injection of these agents, either separately or together, led to accumulation in the vicinity of tumor neovessels without toxic side effects.
  • Combined, local anti-CD40 and IL-2 therapy reduced tumor vascularity and significantly delayed tumor growth in mice.
  • Remarkably, tumor-bearing mice remained disease-free long-term when targeted anti-CD40 and IL-2 were combined with transfers of preactivated antitumor immune cells.
  • In this therapeutic setting, triggering of CD40 on endothelial cells induced an inflammatory response of the vessel wall and facilitated effector cell accumulation in the tumor parenchyma while IL-2 promoted antigen-specific immune cell persistence.
  • We believe this is a novel and highly effective anticancer approach, whereby tumor stroma is "conditioned" for enhanced immune cell entry and survival, facilitating immune-mediated tumor destruction and leading to a sustained antitumor response.
  • [MeSH-major] Adenoma, Islet Cell. Antibodies. Antigens, CD40 / immunology. Immunotherapy, Adoptive. Interleukin-2 / immunology. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2004 Aug;10(8):534-9 [15282531.001]
  • [Cites] Trends Immunol. 2007 Nov;28(11):467-73 [17981086.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Mol Cell Biol. 1985 Dec;5(12):3610-6 [3915782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7487-91 [2217180.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2985-9 [1532662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12135-9 [7527552.001]
  • [Cites] J Exp Med. 1995 Jul 1;182(1):33-40 [7540655.001]
  • [Cites] Cell Immunol. 1999 Dec 15;198(2):87-95 [10648122.001]
  • [Cites] J Vet Med Sci. 2000 Oct;62(10):1101-4 [11073083.001]
  • [Cites] J Immunol Methods. 2001 Feb 1;248(1-2):139-47 [11223075.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1549-59 [11733570.001]
  • [Cites] J Exp Med. 2002 Feb 18;195(4):423-35 [11854356.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):719-25 [11857345.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1659-65 [11861281.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1462-70 [11888921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6 [11929985.001]
  • [Cites] J Immunol. 2003 Mar 1;170(5):2727-33 [12594303.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5051-63 [14607902.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):393-403 [14667506.001]
  • [Cites] Expert Opin Biol Ther. 2004 Apr;4(4):455-68 [15102596.001]
  • [Cites] J Immunol. 2004 May 15;172(10):5861-9 [15128765.001]
  • [Cites] Immunity. 1995 Jun;2(6):573-85 [7796292.001]
  • [Cites] J Leukoc Biol. 1995 Aug;58(2):209-16 [7543921.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1857-64 [7500031.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):747-52 [8760829.001]
  • [Cites] Immunity. 1996 Oct;5(4):319-30 [8885865.001]
  • [Cites] Nature. 1998 Feb 5;391(6667):591-4 [9468137.001]
  • [Cites] J Immunol. 1997 Dec 1;159(11):5640-7 [9548507.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):478-80 [9624004.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):480-3 [9624005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3957-62 [10097145.001]
  • [Cites] Nat Med. 1999 May;5(5):548-53 [10229232.001]
  • [Cites] Nat Med. 1999 Jul;5(7):774-9 [10395322.001]
  • [Cites] Nat Med. 1999 Jul;5(7):780-7 [10395323.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1094-101 [15459006.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1137-46 [16151407.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):786-95 [16507894.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):685-90 [16864602.001]
  • [Cites] J Exp Med. 2006 Oct 30;203(11):2441-50 [17043144.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):876-83 [17327609.001]
  • [Cites] Nat Med. 2007 Mar;13(3):354-60 [17334371.001]
  • [Cites] Cancer Cell. 2007 Jun;11(6):539-54 [17560335.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):6686-95 [17982058.001]
  • [Cites] Eur J Immunol. 2004 Oct;34(10):2635-41 [15368278.001]
  • (PMID = 18398504.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD40; 0 / GTPase-Activating Proteins; 0 / Interleukin-2; 0 / Peptides; 0 / Ralbp1 protein, mouse; 0 / Recombinant Fusion Proteins
  • [Other-IDs] NLM/ PMC2289791
  •  go-up   go-down


18. Alzahrani AS, Al-Khaldi N, Shi Y, Al-Rijjal RA, Zou M, Baitei EY, Amin T: Diagnosis by serendipity: Cushing syndrome attributable to cortisol-producing adrenal adenoma as the initial manifestation of multiple endocrine neoplasia type 1 due to a rare splicing site MEN1 gene mutation. Endocr Pract; 2008 Jul-Aug;14(5):595-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis by serendipity: Cushing syndrome attributable to cortisol-producing adrenal adenoma as the initial manifestation of multiple endocrine neoplasia type 1 due to a rare splicing site MEN1 gene mutation.
  • OBJECTIVE: To report a case that highlights the potential for Cushing syndrome to be the first manifestation of multiple endocrine neoplasia type 1 (MEN 1) syndrome and to describe the rare underlying genetic mutation and the heterogeneous manifestations of the syndrome within the same family.
  • RESULTS: A 16-year-old girl who was not known to have any medical illness and had no known family history of MEN 1 syndrome presented with Cushing syndrome attributable to a cortisol-producing adrenal adenoma.
  • She did not have clinical, biochemical, or radiologic evidence of islet cell pancreatic tumors.
  • Most cases are due to corticotropin-producing pituitary adenomas.
  • [MeSH-major] Adrenocortical Adenoma / pathology. Cushing Syndrome / diagnosis. Hydrocortisone / secretion. Multiple Endocrine Neoplasia Type 1 / pathology


19. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM: Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res; 2006 Feb 01;66(3):1434-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antibodies and other macromolecular therapeutics can gain access to tumor cells via leaky tumor vessels.
  • We addressed this issue by examining the distribution of extravasated antibodies in islet cell tumors of RIP-Tag2 transgenic mice and implanted Lewis lung carcinomas using fluorescence and confocal microscopic imaging.
  • Anti-E-cadherin antibody, which targets epitopes on tumor cells of RIP-Tag2 adenomas, was the only antibody to achieve detectable levels within tumor cell clusters at 6 hours after i.v. injection.
  • Treatment for 7 days with AG-013736, a potent inhibitor of VEGF signaling, reduced the tumor vascularity by 86%.
  • The overall area density of extravasated IgG/antibodies decreased after treatment but the change was less than the reduction in vascularity and actually increased when expressed per surviving tumor vessel.
  • Accumulation of anti-E-cadherin antibody in tumor cell clusters was similarly affected.
  • The patchy pattern of antibodies in stroma after treatment qualitatively resembled untreated tumors and surprisingly coincided with sleeves of basement membrane left behind after pruning of tumor vessels.
  • Together, the findings suggest that antibody transport increases from surviving tumor vessels after normalization by inhibition of VEGF signaling.
  • Antibodies preferentially distribute to tumor stroma but also accumulate on tumor cells if binding sites are accessible.
  • [MeSH-major] Adenoma, Islet Cell / blood supply. Adenoma, Islet Cell / immunology. Antibodies, Neoplasm / metabolism. Carcinoma, Lewis Lung / blood supply. Carcinoma, Lewis Lung / immunology. Immunoglobulin G / metabolism. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452199.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 59157; United States / NHLBI NIH HHS / HL / P01 HL024136; United States / NCI NIH HHS / CA / P50 CA 90270; United States / NHLBI NIH HHS / HL / HL 24136; United States / NCI NIH HHS / CA / CA 82923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cadherins; 0 / Imidazoles; 0 / Immunoglobulin G; 0 / Indazoles; 0 / Vascular Endothelial Growth Factor A; 9001-31-4 / Fibrin; C9LVQ0YUXG / axitinib
  •  go-up   go-down


20. Klimstra DS: Nonductal neoplasms of the pancreas. Mod Pathol; 2007 Feb;20 Suppl 1:S94-112
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the majority of pancreatic neoplasms are infiltrating ductal adenocarcinomas or other neoplasms with ductal differentiation, neoplasms with acinar, endocrine, mixed, or uncertain differentiation constitute a diverse and distinctive group.
  • The most common and best-characterized nonductal neoplasms are pancreatic endocrine neoplasm, acinar cell carcinoma, pancreatoblastoma, and solid pseudopapillary neoplasm.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenoma, Islet Cell / pathology. Carcinoma, Acinar Cell / pathology. Carcinoma, Islet Cell / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486055.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, Doglioni C, Capella C, Solcia E: Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol; 2009 Jan;40(1):30-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.
  • Currently used histopathologic criteria for the diagnosis of pancreatic endocrine tumors are still under discussion as far as to their capacity to identify prognostically different tumor subsets, which are potentially helpful for patient management.
  • One hundred fifty-five pancreatic endocrine tumors encompassing all the main histologic types and stages, operated with intention to cure and then followed up for a median 126 months, were carefully investigated histologically to identify prognostically informative parameters at univariable, bivariable, and multivariable analysis.
  • Ki67 index, mitotic rate, neuroinvasion with or without vascular, peritumoral or stromal infiltrative patterns, as well as tumor size, and association with endocrine syndromes other than insulinoma proved effective in predicting recurrence and disease-specific death among well-differentiated tumors.
  • The TNM system proved to be highly predictive of patient outcome and easy to combine with histologic and clinicopathologic parameters to classify pancreatic endocrine tumors into groups of increasing malignant potential.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Carcinoma, Islet Cell / pathology. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. Humans. Insulinoma / diagnosis. Insulinoma / metabolism. Insulinoma / pathology. Ki-67 Antigen / analysis. Mitotic Index. Necrosis / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Tumor Burden

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715612.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


22. Yamaguchi T, Takahashi H, Kagawa R, Takeda R, Sakata S, Yamamoto M, Iwasa Y: Nonfunctioning pancreatic endocrine tumor presenting with hemorrhage from isolated gastric varices. Am Surg; 2005 Dec;71(12):1027-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonfunctioning pancreatic endocrine tumor presenting with hemorrhage from isolated gastric varices.
  • Hemorrhage from gastric varices due to left-sided portal hypertension is an unusual presentation for pancreatic endocrine tumor.
  • A case of pancreatic endocrine tumor presenting with gastric variceal hemorrhage secondary to left-sided portal hypertension associated with splenic vein occlusion is presented.
  • Surveys to identify the cause of gastric varices by an abdominal CT, MRCP, and abdominal angiography revealed splenic vein occlusion secondarily attributed to the pancreatic tail tumor and splenomegaly.
  • The pancreatic tumor was suspected to be a resectable endocrine tumor.
  • By the histological examination, the diagnosis of nonfunctioning pancreatic endocrine tumor with malignant potential was determined.
  • In this case, the unusual presentation for pancreatic endocrine tumors such as a gastric variceal hemorrhage had an advantage that led to early presentation prior to the development of metastases with possible curative surgery.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Esophageal and Gastric Varices / diagnosis. Gastrointestinal Hemorrhage / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447473.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Serra S, Asa SL, Chetty R: Intracytoplasmic inclusions (including the so-called "rhabdoid" phenotype) in pancreatic endocrine tumors. Endocr Pathol; 2006;17(1):75-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracytoplasmic inclusions (including the so-called "rhabdoid" phenotype) in pancreatic endocrine tumors.
  • The cytoplasm of pancreatic endocrine tumors (PET) can show a diverse range of appearances from clear, to oncocytic, to intracellular mucin accumulation, and the presence of intracytoplasmic inclusions.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Inclusion Bodies / pathology. Multiple Endocrine Neoplasia Type 1 / pathology. Pancreatic Neoplasms / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1106-10 [15452172.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):642-9 [12717248.001]
  • [Cites] Hum Pathol. 2000 Dec;31(12):1455-65 [11150370.001]
  • [Cites] Mod Pathol. 2002 Feb;15(2):146-53 [11850543.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):271-3 [15043320.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1329-38 [11023094.001]
  • (PMID = 16760583.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Zhou J, Dong M, Kong F, Li Y, Tian Y: Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases. J Surg Oncol; 2009 Sep 1;100(3):273-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases.
  • BACKGROUND: To discuss the advantage of central pancreatectomy in the patients with benign tumors of the neck and body of the pancreas.
  • The operation is carried out by exposition of the pancreatic neck and body involved by the lesion.
  • RESULTS: Central pancreatectomy was done in eight patients including five mucinous cystadenomas, one serious cystadenoma, one insulinoma and one nonfunctional islet cell tumor.
  • Pancreatic fistula occurred in three cases and was treated conservatively.
  • CONCLUSION: Central pancreatectomy is a safe technique for benign tumors of the pancreatic neck and body, especially when the enucleation is very difficult.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / surgery. Adult. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Female. Humans. Insulinoma / surgery. Male. Middle Aged. Pancreatic Fistula / etiology. Pancreatic Fistula / therapy. Postoperative Complications. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267362.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Nakano K, Yamashita S, Soma I, Hayashi N, Higaki N, Murakami M, Hayashida H, Kan K, Ichihara T, Sakon M, Ayata M: [A case of nonfunctioning islet cell tumor with extensive calcification]. Nihon Shokakibyo Gakkai Zasshi; 2009 Oct;106(10):1494-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of nonfunctioning islet cell tumor with extensive calcification].
  • Abdominal CT and magnetic resonance imaging (MRI) findings showed a calcified tumor 5 cm in diameter with a smooth surface.
  • The tumor mainly showed calcification at it center and a partially solid element around it margin which was enhanced in the early phase.
  • Pathological and immunohistochemical studies revealed a nonfunctioning islet cell tumor with calcification.
  • A nonfunctioning islet cell tumor with central calcification formation as it grew to a maximum diameter of 7 cm is rare.
  • When diagnosing pancreatic tumors it must be kept in mind that some nonfunctioning islet cell tumors of the pancreas can show nontypical features such as calcification formation.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Calcinosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834297.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Namasivayam S, Salman K, Mittal PK, Martin D, Small WC: Hypervascular hepatic focal lesions: spectrum of imaging features. Curr Probl Diagn Radiol; 2007 May-Jun;36(3):107-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common hypervascular liver lesions include hemangioma, focal nodular hyperplasia, hepatocellular adenoma, hepatocellular carcinoma, fibrolamellar carcinoma, and metastases from primary tumors such as islet cell tumor, carcinoid, renal cell carcinoma, melanoma, and thyroid carcinoma.
  • [MeSH-minor] Adenoma / diagnosis. Hemangioendothelioma / diagnosis. Hemangioma. Humans. Liver / blood supply. Liver Cirrhosis / diagnosis. Melanoma / diagnosis. Melanoma / pathology. Melanoma / secondary. Necrosis. Neoplasm Invasiveness. Portal Vein / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484954.001).
  • [ISSN] 0363-0188
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Yang W, Chen MH, Yan K, Wu W, Dai Y, Zhang H: Differential diagnosis of non-functional islet cell tumor and pancreatic carcinoma with sonography. Eur J Radiol; 2007 Jun;62(3):342-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of non-functional islet cell tumor and pancreatic carcinoma with sonography.
  • OBJECTIVE: To investigate the differential diagnosis of non-functional islet cell tumor (NFICT) and pancreatic ductal adenocarcinoma (pancreatic carcinoma) with clinical presentation and sonographic features.
  • MATERIALS AND METHODS: Twenty cases of NFICT were investigated in the study, and 41 cases of pancreatic carcinoma were included as the control group.
  • Among them, 5 NFICT and 32 pancreatic carcinomas underwent CEUS with SonoVue.
  • RESULTS: Statistic analysis showed four significant factors in differential diagnosis for NFICT and pancreatic carcinoma, including age (P<0.001), tumor size (P=0.006), tumor margin (P<0.001) and vascularity of tumor (P=0.004).
  • When the patient is younger than 60 years, and tumor is smaller than 5 cm with well-defined margin and hypervascular, it would be most likely a NFICT other than pancreatic carcinoma.
  • NFICT often shows early enhancement and more homogeneous infusion than pancreatic carcinoma on CEUS (P=0.005 and 0.008).
  • CONCLUSIONS: Sonography is able to provide useful differential information for NFICT, which is often misdiagnosed as pancreatic carcinoma.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Pancreas / ultrasonography. Pancreatic Neoplasms / diagnosis. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17412543.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


28. Levy MJ, Smyrk TC, Reddy RP, Clain JE, Harewood GC, Kendrick ML, Pearson RK, Petersen BT, Rajan E, Topazian MD, Wang KK, Wiersema MJ, Yusuf TE, Chari ST: Endoscopic ultrasound-guided trucut biopsy of the cyst wall for diagnosing cystic pancreatic tumors. Clin Gastroenterol Hepatol; 2005 Oct;3(10):974-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided trucut biopsy of the cyst wall for diagnosing cystic pancreatic tumors.
  • The aim of this study was to determine whether the tissue obtained by endoscopic ultrasound-guided trucut biopsy (EUS TCB) is sufficient for histologic diagnosis of cystic pancreatic tumors (CPTs).
  • Final diagnoses included serous cystadenoma (SCA, n=5), islet cell tumor (n=2), mixed seromucinous lesion (n=1), polycystic disease of the pancreas (n=1), and pseudocyst (n=1).
  • In the fourth patient with an SCA, the TCB result ruled out metastatic disease from locally recurrent lung cancer, allowing a narrowed radiation field.
  • EUS TCB confirmed the need for surgery in 2 patients with an islet cell tumor.
  • [MeSH-major] Biopsy / methods. Endoscopy, Gastrointestinal / methods. Pancreatic Cyst / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenoma, Islet Cell / pathology. Adult. Aged. Aged, 80 and over. Cystadenoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pancreatic Pseudocyst / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2005 Oct;3(10):964-6 [16234040.001]
  • (PMID = 16234042.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Zhong L: Magnetic resonance imaging in the detection of pancreatic neoplasms. J Dig Dis; 2007 Aug;8(3):128-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging in the detection of pancreatic neoplasms.
  • Recently, with the rapid scanning time and improved image quality, outstanding advances in magnetic resonance (MR) methods have resulted in an increase in the use of MRI for patients with a variety of pancreatic neoplasms.
  • The non-invasive all-in-one MR multi-imaging techniques may provide the comprehensive information needed for the preoperative diagnosis and evaluation of pancreatic neoplasms.
  • Pancreatic neoplasms include primary tumors and pancreatic metastases.
  • Primary tumors of the pancreas may be mainly classified as ductal adenocarcinomas, cystic tumors and islet cell tumors (ICT).
  • Pancreatic adenocarcinomas can be diagnosed in a MRI study depending on direct evidence or both direct and indirect evidence.
  • The combined MRI features of a focal pancreatic mass, pancreatic duct dilatation and parenchymal atrophy are highly suggestive of a ductal adenocarcinoma.
  • Most cystic neoplasms of the pancreas are either microcystic adenomas or mucinous cystic neoplasms.
  • Intraductal papillary mucinous tumors are the uncommon low-grade malignancy of the pancreatic duct.
  • [MeSH-major] Cholangiopancreatography, Magnetic Resonance. Magnetic Resonance Angiography. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / pathology. Humans. Neoplasms, Cystic, Mucinous, and Serous / diagnosis. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreas / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650223.001).
  • [ISSN] 1751-2972
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 10
  •  go-up   go-down


30. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E: Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest; 2009 Nov;119(11):3356-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.
  • Tumor growth and progression rely upon angiogenesis, which is regulated by pro- and antiangiogenic factors, including members of the semaphorin family.
  • By analyzing 3 different mouse models of multistep carcinogenesis, we show here that during angiogenesis, semaphorin 3A (Sema3A) is expressed in ECs, where it serves as an endogenous inhibitor of angiogenesis that is present in premalignant lesions and lost during tumor progression.
  • Pharmacologic inhibition of endogenous Sema3A during the angiogenic switch, the point when pretumoral lesions initiate an angiogenic phase that persists throughout tumor growth, enhanced angiogenesis and accelerated tumor progression.
  • By contrast, when, during the later stages of carcinogenesis following endogenous Sema3A downmodulation, Sema3A was ectopically reintroduced into islet cell tumors by somatic gene transfer, successive waves of apoptosis ensued, first in ECs and then in tumor cells, resulting in reduced vascular density and branching and inhibition of tumor growth and substantially extended survival.
  • Further, long-term reexpression of Sema3A markedly improved pericyte coverage of tumor blood vessels, something that is thought to be a key property of tumor vessel normalization, and restored tissue normoxia.
  • We conclude, therefore, that Sema3A is an endogenous and effective antiangiogenic agent that stably normalizes the tumor vasculature.
  • [MeSH-minor] Adenoma, Islet Cell / blood supply. Adenoma, Islet Cell / physiopathology. Animals. Antigens, CD29 / metabolism. Cell Hypoxia. Cell Movement. Disease Models, Animal. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Uterine Cervical Neoplasms / blood supply. Uterine Cervical Neoplasms / physiopathology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):584-93 [16445911.001]
  • [Cites] Diabetes. 2006 Apr;55(4):875-84 [16567506.001]
  • [Cites] Trends Biochem Sci. 2006 Apr;31(4):231-9 [16530415.001]
  • [Cites] Blood. 2006 May 15;107(10):3892-901 [16424390.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):81-91 [16728327.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1661-7 [16684957.001]
  • [Cites] Nat Med. 2006 Dec;12(12):1380-9 [17099709.001]
  • [Cites] J Clin Invest. 2000 Feb;105(3):261-70 [10675351.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):35-45 [11025205.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Mech Dev. 2001 Nov;109(1):115-9 [11677062.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):193-202 [12086877.001]
  • [Cites] Nat Med. 2002 Sep;8(9):918-21 [12205444.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9 [12192090.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):933-41 [12370271.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):496-503 [12584749.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Nature. 2003 Jul 24;424(6947):391-7 [12879061.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42985-91 [12933805.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):393-403 [14667506.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1008-15 [14871832.001]
  • [Cites] Genes Dev. 2004 Feb 15;18(4):435-47 [14977921.001]
  • [Cites] Mol Cell Neurosci. 2004 Apr;25(4):722-31 [15080899.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):421-5 [15157151.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):623-33 [15343380.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9051-5 [7692444.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25570-7 [7592728.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2930-5 [8610145.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]
  • [Cites] Clin Ther. 2006 Nov;28(11):1779-802 [17212999.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):53-67 [17222790.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1451-60 [17308083.001]
  • [Cites] J Biol Chem. 2007 Sep 7;282(36):26294-305 [17569671.001]
  • [Cites] Cell. 2007 Nov 2;131(3):463-75 [17981115.001]
  • [Cites] Front Biosci. 2008;13:2653-9 [17981740.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):421-31 [17768598.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2674-80 [18180379.001]
  • [Cites] Nat Med. 2008 Mar;14(3):255-7 [18278052.001]
  • [Cites] Circ Res. 2008 Mar 14;102(5):562-70 [18202311.001]
  • [Cites] Trends Biochem Sci. 2008 Apr;33(4):161-70 [18374575.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1155-71 [18458115.001]
  • [Cites] Nature. 2008 May 15;453(7193):410-4 [18418378.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):632-45 [18580951.001]
  • [Cites] PLoS One. 2008;3(9):e3287 [18818766.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):942-56 [19029957.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1294-300 [9102216.001]
  • [Cites] Science. 1999 Apr 30;284(5415):808-12 [10221914.001]
  • [Cites] J Neurochem. 1999 Sep;73(3):961-71 [10461885.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1260-71 [15520858.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):193-211 [15972964.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):193-200 [16015319.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6167-77 [16024618.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):870-9 [16113679.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8317-23 [16166308.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):1-11 [16356825.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):198-211 [16397233.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1220-5 [16258027.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):651-8 [16325811.001]
  • (PMID = 19809158.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP04127; Italy / Telethon / / GGP09175; United States / NIDDK NIH HHS / DK / DK59936; United States / NIAAA NIH HHS / AA / P60 AA11999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD29; 0 / Semaphorin-3A
  •  go-up   go-down


31. Du YC, Lewis BC, Hanahan D, Varmus H: Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol; 2007 Oct 16;5(10):e276
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion.
  • Tumors develop through multiple stages, implicating multiple effectors, but the tools to assess how candidate genes contribute to stepwise tumor progression have been limited.
  • We have developed a novel system in which progression of phenotypes in a mouse model of pancreatic islet cell tumorigenesis can be used to measure the effects of genes introduced by cell-type-specific infection with retroviral vectors.
  • Like RIP-Tag mice, RIP-Tag; RIP-tva bitransgenic mice develop isolated carcinomas by approximately 14 wk of age, after progression through well-defined stages that are similar to aspects of human tumor progression, including hyperplasia, angiogenesis, adenoma, and invasive carcinoma.
  • Similar infection with vectors carrying cDNA encoding either of two progression factors, a dominant-negative version of cadherin 1 (dnE-cad) or Bcl-xL, accelerated the formation of islet tumors with invasive properties and pancreatic lymph node metastasis.
  • To begin studying the mechanism by which Bcl-xL, an anti-apoptotic protein, promotes invasion and metastasis, RIP-Tag; RIP-tva pancreatic islet tumor cells were infected in vitro with RCASBP-Bcl-xL.
  • Although no changes were observed in rates of proliferation or apoptosis, Bcl-xL altered cell morphology, remodeled the actin cytoskeleton, and down-regulated cadherin 1; it also induced cell migration and invasion, as evaluated using two-chamber transwell assays.
  • In addition, myosin Va was identified as a novel Bcl-xL-interacting protein that might mediate the effects of Bcl-xL on tumor cell migration and invasion.


32. Auerbach SS, Bristol DW, Peckham JC, Travlos GS, Hébert CD, Chhabra RS: Toxicity and carcinogenicity studies of methylene blue trihydrate in F344N rats and B6C3F1 mice. Food Chem Toxicol; 2010 Jan;48(1):169-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of pancreatic islet cell adenoma and adenoma or carcinoma (combined) were increased in all dosed groups of male rats, but increases were statistically significant in 25mg/kg bw/day males only and the dose-response was non-linear.
  • There was a corresponding increase in the incidence of pancreatic islet cell hyperplasia but statistically significant only in the 50mg/kg bw/day male rats.
  • There were no significant increases in neoplastic transformation observed in the mice; however, positive trends were noted for adenoma or carcinoma (combined) of the small intestine and malignant lymphoma.
  • [MeSH-minor] Animals. Blood Cell Count. Body Weight / drug effects. Carcinogenicity Tests. Dose-Response Relationship, Drug. Female. Hematopoietic Stem Cells / drug effects. Hyperplasia / chemically induced. Hyperplasia / pathology. Kaplan-Meier Estimate. Lung / pathology. Male. Mammary Neoplasms, Experimental / chemically induced. Mammary Neoplasms, Experimental / pathology. Mice. Mice, Inbred Strains. Neoplasms / chemically induced. Neoplasms / pathology. Rats. Rats, Inbred F344. Sex Characteristics. Species Specificity. Survival Analysis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ltd.
  • (PMID = 19804809.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Grant] United States / FDA HHS / BB / 1 Z01 ESO45004-11 BB; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; T42P99266K / Methylene Blue
  •  go-up   go-down


33. Adissu HA, Turner PV: Insulinoma and squamous cell carcinoma with peripheral polyneuropathy in an aged Sprague-Dawley rat. J Am Assoc Lab Anim Sci; 2010 Nov;49(6):856-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulinoma and squamous cell carcinoma with peripheral polyneuropathy in an aged Sprague-Dawley rat.
  • Pancreatic islet cell adenoma, oral squamous cell carcinoma, peripheral polyneuropathy, and multiple age-associated degenerative lesions were diagnosed in an aged Sprague-Dawley rat presenting with polyuria, polydypsia, dehydration, anorexia, weight loss, and posterior weakness.
  • Microscopically, the islet cell adenoma was encapsulated by fibrous tissue and composed of packets of oval-to-polygonal monomorphic cells in a fibrovascular stroma.
  • The oral squamous cell carcinoma, grossly presenting as gingival ulceration, was composed of nests and cords of squamous epithelial cells that focally eroded and infiltrated the hard palate and resulted in degeneration of the maxillary nerve.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Gingival Neoplasms / veterinary. Insulinoma / veterinary. Pancreatic Neoplasms / veterinary. Peripheral Nervous System / pathology. Polyneuropathies / veterinary. Rats

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Toxicol. 1992;66(7):496-502 [1444814.001]
  • [Cites] J Neuropathol Exp Neurol. 1989 Jul;48(4):399-412 [2543797.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Nov-Dec;34(6):471-5 [9826281.001]
  • [Cites] Acta Neuropathol. 2004 Dec;108(6):503-14 [15365726.001]
  • [Cites] Toxicol Pathol. 2001 May-Jun;29(3):353-62 [11442021.001]
  • [Cites] Brain Res. 2002 Aug 23;947(1):84-9 [12144856.001]
  • [Cites] Diabetes Metab Res Rev. 2003 Sep-Oct;19(5):392-400 [12951647.001]
  • [Cites] J Natl Cancer Inst. 1967 Jul;39(1):17-32 [4291142.001]
  • [Cites] Diabetologia. 1968 Jan;4(1):44-7 [4907148.001]
  • [Cites] J Comp Pathol. 1982 Jan;92(1):139-47 [6279704.001]
  • [Cites] Acta Neuropathol. 1983;59(1):63-9 [6837269.001]
  • [Cites] Vet Pathol. 1983 May;20(3):291-7 [6308877.001]
  • [Cites] Vet Pathol. 1986 Jan;23(1):11-5 [3004001.001]
  • [Cites] J Vet Intern Med. 1987 Apr-Jun;1(2):86-90 [2851653.001]
  • [Cites] Lab Anim. 1998 Oct;32(4):457-66 [9807760.001]
  • (PMID = 21205453.001).
  • [ISSN] 1559-6109
  • [Journal-full-title] Journal of the American Association for Laboratory Animal Science : JAALAS
  • [ISO-abbreviation] J. Am. Assoc. Lab. Anim. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2994055
  •  go-up   go-down


34. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H, Yasui W: Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol; 2005 Oct;207(2):185-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating islet-derived family, member 4 (Reg IV) is a candidate marker for cancer and inflammatory bowel disease.
  • Insulin-producing beta cells of the endocrine pancreas were positive for Reg IV.
  • No association was found between Reg IV expression and clinical characteristics such as tumour stage and patient prognosis.
  • Of 36 colorectal adenocarcinomas, 13 (36.1%) were positive for Reg IV, which was associated with tumour stage (p = 0.0379, Fisher's exact test).
  • These data suggest that Reg IV is expressed by gastrointestinal and pancreatic tumours, including adenocarcinomas and carcinoid tumours, and that Reg IV is associated with intestinal and neuroendocrine differentiation of the stomach and gastric carcinoma.
  • [MeSH-minor] Adenoma / chemistry. Biomarkers, Tumor / analysis. Blotting, Western / methods. Breast Neoplasms / chemistry. Carcinoid Tumor / chemistry. Cell Differentiation / physiology. Cell Line, Tumor. Colon / metabolism. Colorectal Neoplasms / chemistry. Female. Humans. Immunohistochemistry / methods. Intestine, Small / metabolism. Lung Neoplasms / chemistry. Pancreas / metabolism. Pancreatic Neoplasms / chemistry. Phenotype. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16086444.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Neoplasm Proteins; 0 / REG4 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


35. Merritt JL 2nd, Davis DM, Pittelkow MR, Babovic-Vuksanovic D: Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations. Am J Med Genet A; 2006 Aug 1;140(15):1669-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations.
  • Acrochordons are frequently encountered benign skin lesions that may occasionally represent underlying pathology.
  • Pancreatic islet-cell tumors are rare neoplasms and few cases have been described in patients with tuberous sclerosis complex (TSC).
  • Further evaluation revealed pancreatic islet cell tumors.
  • Additionally, mutations in TSC2 gene may be a risk factor for developing pancreatic islet-cell tumors.
  • [MeSH-major] Adenoma, Islet Cell / genetics. Adenoma, Islet Cell / pathology. Mutation. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. Skin Diseases / genetics. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / genetics


36. Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ: Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg; 2007 Nov;11(11):1460-7; discussion 1467-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients.
  • The natural history of pancreatic neuroendocrine tumors (PNET) remains poorly defined.
  • As PNETs have a better prognosis than adenocarcinoma, concerns regarding the morbidity and mortality of pancreatic surgery and neoplasms should not preclude resection.
  • [MeSH-minor] Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / surgery. Adult. Aged. Cell Differentiation. Female. Humans. Male. Middle Aged. Patient Selection. Prognosis. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jan 15;65(2):354-7 [2153046.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] Ann Intern Med. 1949 Oct;31(4):624-7 [15390535.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] World J Surg. 2007 Mar;31(3):579-85 [17219270.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):718-25; discussion 725-7 [15249403.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1806-10 [16085691.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):327-31 [16504877.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1806-9 [15188511.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1766-73 [16030115.001]
  • [Cites] ANZ J Surg. 2001 Aug;71(8):475-82 [11504292.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 1995 Nov;222(5):638-45 [7487211.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1083-92 [16322345.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):962-9 [15525824.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):173-80 [17667493.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):295-9; discussion 299-300 [7887797.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Dig Surg. 2005;22(3):157-62 [16043962.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):469-72 [15313691.001]
  • [Cites] J Surg Oncol. 2004 Jan;85(1):1-3 [14696080.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):347-56 [16504879.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] Ann Surg. 2005 May;241(5):776-83; discussion 783-5 [15849513.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 17846854.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Ali A, Serra S, Asa SL, Chetty R: The predictive value of CK19 and CD99 in pancreatic endocrine tumors. Am J Surg Pathol; 2006 Dec;30(12):1588-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The predictive value of CK19 and CD99 in pancreatic endocrine tumors.
  • Prediction of behavior in pancreatic endocrine tumors (PETs) is reliant on clinicopathologic features.
  • Although not statistically significant, CK19-negative tumors tended to be smaller than the average tumor size in the series (2.5 vs. 3.6 cm).
  • [MeSH-major] Adenoma, Islet Cell / metabolism. Antigens, CD / metabolism. Carcinoma, Islet Cell / metabolism. Cell Adhesion Molecules / metabolism. Keratin-19 / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Middle Aged. Mitosis. Predictive Value of Tests. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122516.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Keratin-19
  •  go-up   go-down


38. Xian X, Håkansson J, Ståhlberg A, Lindblom P, Betsholtz C, Gerhardt H, Semb H: Pericytes limit tumor cell metastasis. J Clin Invest; 2006 Mar;116(3):642-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericytes limit tumor cell metastasis.
  • Previously we observed that neural cell adhesion molecule (NCAM) deficiency in beta tumor cells facilitates metastasis into distant organs and local lymph nodes.
  • Here, we show that NCAM-deficient beta cell tumors grew leaky blood vessels with perturbed pericyte-endothelial cell-cell interactions and deficient perivascular deposition of ECM components.
  • Conversely, tumor cell expression of NCAM in a fibrosarcoma model (T241) improved pericyte recruitment and increased perivascular deposition of ECM molecules.
  • Together, these findings suggest that NCAM may limit tumor cell metastasis by stabilizing the microvessel wall.
  • To directly address whether pericyte dysfunction increases the metastatic potential of solid tumors, we studied beta cell tumorigenesis in primary pericyte-deficient Pdgfb(ret/ret) mice.
  • This resulted in beta tumor cell metastases in distant organs and local lymph nodes, demonstrating a role for pericytes in limiting tumor cell metastasis.
  • These data support a new model for how tumor cells trigger metastasis by perturbing pericyte-endothelial cell-cell interactions.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / prevention & control. Pancreatic Neoplasms / pathology. Pericytes / physiology
  • [MeSH-minor] Animals. Cell Communication / genetics. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Fibrosarcoma / blood supply. Fibrosarcoma / genetics. Fibrosarcoma / metabolism. Fibrosarcoma / pathology. Mice. Mice, Inbred C57BL. Mice, Knockout. Neovascularization, Pathologic / metabolism. Neural Cell Adhesion Molecules / deficiency. Neural Cell Adhesion Molecules / genetics. Neural Cell Adhesion Molecules / physiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1991 Jun;138(6):1335-47 [1711288.001]
  • [Cites] Cell Struct Funct. 1986 Sep;11(3):245-52 [3768962.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2451-60 [9059333.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Science. 1997 Jul 11;277(5323):242-5 [9211853.001]
  • [Cites] Am J Surg. 1997 Sep;174(3):251-7 [9324132.001]
  • [Cites] Nat Med. 1999 Mar;5(3):286-91 [10086383.001]
  • [Cites] Curr Top Pathol. 1999;93:27-33 [10339896.001]
  • [Cites] Development. 1999 Jun;126(14):3047-55 [10375497.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8630-8 [15574770.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):102-11 [15661540.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Mar;5(2):221-30 [15833051.001]
  • [Cites] Tumour Biol. 2005 Mar-Apr;26(2):103-12 [15897690.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] Oncology. 2005;69(2):159-66 [16127287.001]
  • [Cites] Brain Res Bull. 2000 Mar 15;51(5):363-9 [10715555.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Dev Dyn. 2001 Jan;220(1):60-73 [11146508.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):672-82 [11179212.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] J Cell Biol. 2001 Apr 30;153(3):543-53 [11331305.001]
  • [Cites] Cells Tissues Organs. 2001;169(1):1-11 [11340256.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Bioessays. 2001 Jun;23(6):494-507 [11385629.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7627-34 [11606404.001]
  • [Cites] Circulation. 2002 Jan 1;105(1):112-7 [11772885.001]
  • [Cites] Glycobiology. 2002 Jan;12(1):47-63 [11825886.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):801-13 [11891179.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] Physiol Rev. 2002 Jul;82(3):673-700 [12087132.001]
  • [Cites] EMBO J. 2002 Aug 15;21(16):4307-16 [12169633.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Nat Med. 2003 Jun;9(6):685-93 [12778167.001]
  • [Cites] Br J Dermatol. 2003 May;148(5):971-80 [12786828.001]
  • [Cites] Genes Dev. 2003 Aug 1;17(15):1835-40 [12897053.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1142-51 [14561699.001]
  • [Cites] J Cell Biol. 2003 Oct 27;163(2):209-13 [14581448.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):509-15 [14726469.001]
  • [Cites] PLoS Biol. 2003 Nov;1(2):E52 [14624252.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2725-33 [15087386.001]
  • [Cites] Circ Res. 2004 Apr 30;94(8):1067-74 [15031262.001]
  • [Cites] Nature. 1985 May 9-15;315(6015):115-22 [2986015.001]
  • [Cites] Nature. 1994 Feb 3;367(6462):455-9 [8107803.001]
  • (PMID = 16470244.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neural Cell Adhesion Molecules
  • [Other-IDs] NLM/ PMC1361347
  •  go-up   go-down


39. Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, Raffel A, Knoefel WT, Weihe E, Ruszniewski P, Couvelard A, Komminoth P, Heitz PU, Klöppel G: Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol; 2006 May;30(5):560-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome.
  • It has been suggested that microadenomatosis of the endocrine pancreas is a hallmark of the multiple endocrine neoplasia type 1 syndrome (MEN1).
  • This study attempts to elucidate the relationship between pancreatic microadenomatosis and the MEN1 and von Hippel-Lindau (VHL) syndromes.
  • Pancreatic tissue specimens from 37 patients (with either microadenomatosis or the MEN1 syndrome) were analyzed using immunohistochemistry, confocal laser scanning microscopy, and morphometric methods.
  • Pancreatic microadenomatosis was found in 35 of 37 patients, 28 of whom fulfilled the clinicopathologic criteria and 13 the genetic criteria for MEN1, whereas none of the patients had evidence of a VHL syndrome.
  • In microadenomatosis patients with and without the MEN1 syndrome, a subset of morphologically normal-appearing islets showed increased endocrine cell proliferation.
  • In conclusion, endocrine multihormonal microadenomatosis of the pancreas is a feature of MEN1.
  • In addition, a monohormonal type of pancreatic microadenomatosis was identified that consisted of either insulinomas or glucagon-producing tumors and was not associated with MEN1 or VHL.
  • [MeSH-major] Adenoma, Islet Cell / complications. Adenoma, Islet Cell / pathology. Multiple Endocrine Neoplasia Type 1 / complications. Multiple Endocrine Neoplasia Type 1 / pathology. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. Male. Microscopy, Confocal. Middle Aged. Mutation. Polymerase Chain Reaction. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / genetics. von Hippel-Lindau Disease / pathology


40. Lindberg D, Akerström G, Westin G: Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clin Endocrinol (Oxf); 2007 Jan;66(1):110-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours.
  • OBJECTIVE: We and others have reported loss of heterozygosity (LOH) on chromosome 3p25 in sporadic malignant pancreatic endocrine tumours (PETs).
  • A common region of deletion on chromosome 3p25 contains numerous genes, including VHL and PPARgamma, that have been excluded previously as candidate tumour suppressor genes by DNA sequencing analysis.
  • CONCLUSION: The absence of tumour-specific somatic events in WNT7A and HDAC11 suggests that these genes are unlikely to have a classical tumour suppressor gene role in sporadic malignant PETs.
  • The putative 3p25 tumour suppressor remains to be identified.
  • [MeSH-major] Adenoma, Islet Cell / genetics. Genes, Tumor Suppressor. Histone Deacetylases / genetics. Loss of Heterozygosity. Pancreatic Neoplasms / genetics. Wnt Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201809.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / WNT7A protein, human; 0 / Wnt Proteins; EC 3.5.1.98 / HDAC11 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


41. Sobczak I, Galabova-Kovacs G, Sadzak I, Kren A, Christofori G, Baccarini M: B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis. Oncogene; 2008 Aug 14;27(35):4779-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
  • The extracellular signal-regulated kinase (ERK) pathway is required for the proliferation of cancer cell lines harboring activating BRAF or, to a lesser extent, activating RAS mutations.
  • It is still unclear, however, whether the pathway is required in vivo for tumor development, particularly in tumors in which B-Raf is not mutationally activated.
  • To address the question of whether B-Raf contributed to tumor angiogenesis in vivo we conditionally ablated B-Raf in a model of pancreatic islet carcinoma driven by the functional inactivation of tumor suppressors (RIP1Tag2), which critically depends on angiogenesis for growth.
  • We find that B-Raf is dispensable for the proliferation of tumor cells in culture, but necessary for ERK activation and for the expression of angiogenic factors by tumor cells in vivo and in vitro.
  • The progression from adenoma to carcinoma is also significantly impaired.
  • Thus, endogenous B-Raf contributes to the development of RIP1Tag2 tumors by supporting the stromal response and tumor progression.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Extracellular Signal-Regulated MAP Kinases / metabolism. Islets of Langerhans / pathology. Pancreatic Neoplasms / pathology. Proto-Oncogene Proteins B-raf / physiology
  • [MeSH-minor] Animals. Base Sequence. DNA Primers. Disease Models, Animal. Disease Progression. Enzyme Activation. Immunohistochemistry. Mice. Mice, Knockout. Reverse Transcriptase Polymerase Chain Reaction. Transforming Growth Factor beta / metabolism. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor A / metabolism


42. House MG, Schulick RD: Endocrine tumors of the pancreas. Curr Opin Oncol; 2006 Jan;18(1):23-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumors of the pancreas.
  • PURPOSE OF REVIEW: Neoplasms of the endocrine pancreas, commonly referenced as pancreatic islet cell tumors, are rare, often well differentiated endocrine neoplasms, whose biology remains poorly characterized.
  • This article reviews the current clinical management of pancreatic islet cell tumors and describes the molecular events that have been studied to guide future therapies of these peculiar neoplasms.
  • RECENT FINDINGS: While some islet cell tumors arise in association with the MEN-1 syndrome, the majority of these neoplasms are sporadic lesions whose underlying genetic and molecular events remain largely unknown.
  • Recent work has identified changes in gene expression occurring in metastatic and non-metastatic islet cell tumors, which appear to correlate with the occurrence of lymph node and liver metastases.
  • Epigenetic alterations of select tumor suppressor genes may influence patient survival, and the presence of gene promoter methylation may be used as a prognostic marker system.
  • In addition, multiple molecular alterations, including changes in expression of cellular proteins with migratory, cell cycle or angiogenic functions, have been demonstrated to influence islet cell tumor growth, invasion and metastatic spread.
  • SUMMARY: Understanding the molecular events underlying the biology of pancreatic islet cell tumors will aid the development of accurate prognostic markers and will guide improved therapeutic modalities in the future.
  • [MeSH-major] Adenoma, Islet Cell / therapy. Carcinoma, Islet Cell / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Klastersky J. Curr Opin Oncol. 2006 Jul;18(4):414 [16721138.001]
  • (PMID = 16357560.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Retracted Publication; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / ELL protein, human; 0 / Transcriptional Elongation Factors
  • [Number-of-references] 51
  •  go-up   go-down


43. Nishie A, Obuchi M, Howe J, Dahmoush L, Stolpen A: Small islet cell tumour in the pancreas: diagnostic value of diffusion-weighted MRI. J Med Imaging Radiat Oncol; 2008 Aug;52(4):374-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small islet cell tumour in the pancreas: diagnostic value of diffusion-weighted MRI.
  • We present a case of a small islet cell tumour that was clearly depicted on diffusion-weighted imaging using a free breathing approach and discuss the diagnostic value of this sequence.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18811762.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


44. Magnussen A, Kasman IM, Norberg S, Baluk P, Murray R, McDonald DM: Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels. Cancer Res; 2005 Apr 1;65(7):2712-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels.
  • Integrin alpha(5)beta(1) is overexpressed on endothelial cells of tumor vessels and is uniformly and rapidly accessible to antibodies in the bloodstream.
  • Here, we determined whether antibodies rapidly gain access to integrin overexpressed on the abluminal (basolateral) surface of endothelial cells through vascular leakiness or whether the rapid accessibility results instead because the integrin is overexpressed on the luminal (apical) surface of endothelial cells due to loss of cell polarity.
  • The distributions did not match: anti-alpha(5)beta(1) integrin antibody uniformly labeled the tumor vasculature, but IgG was located in patchy sites of leakage.
  • Together, these findings indicate that the rapid accessibility of alpha(5)beta(1) integrin in RIP-Tag2 tumors results from overexpression of the integrin on the luminal surface of tumor vessels.
  • [MeSH-major] Adenoma, Islet Cell / blood supply. Antibodies / metabolism. Integrin alpha5beta1 / metabolism. Pancreatic Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805270.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-24136; United States / NHLBI NIH HHS / HL / HL-59157; United States / NCI NIH HHS / CA / P50-CA90270
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD31; 0 / Collagen Type IV; 0 / Fibronectins; 0 / Immunoglobulin G; 0 / Integrin alpha5beta1; 9001-31-4 / Fibrin
  •  go-up   go-down


45. Ramachandra C, Manjunath S, Joseph B, Appaji L, Kumari BS, Rao CR, Prabhakaran PS: Mixed exocrine-endocrine pancreatic carcinoma in childhood. Indian J Gastroenterol; 2005 May-Jun;24(3):116
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed exocrine-endocrine pancreatic carcinoma in childhood.
  • A 7-year-old boy with mixed exocrine-endocrine pancreatic cancer is presented.
  • This may be the second reported case of such a tumor in childhood.
  • [MeSH-major] Adenoma, Islet Cell / epidemiology. Carcinoma, Acinar Cell / epidemiology. Pancreatic Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041106.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 5
  •  go-up   go-down


46. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P, Bedossa P: Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res; 2008 Oct 15;14(20):6634-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors.
  • PURPOSE: Tumor hypoxia is associated with poor prognosis and resistance to treatment.
  • Our aim was to assess the expression of proteins that act as cellular oxygen sensors, directly regulating the hypoxia inducible factor (HIF) pathway, i.e., prolyl hydroxylase domain proteins (PHD)-1, PHD-2, PHD-3, and FIH in pancreatic endocrine tumors (PET).
  • FIH stromal expression was found in 23% of PETs and correlated with higher FIH nuclear expression (P = 0.0004) and poorer disease-free survival (P = 0.0018).
  • CONCLUSION: HIF regulatory proteins are highly expressed in PET and their expression is correlated with tumor metastases, tumor recurrence, and prognosis.
  • These molecules that play an important role in the control of hypoxia-induced genes may have a function in the regulation of cellular proliferation and differentiation during endocrine tumorigenesis.
  • [MeSH-major] Cell Hypoxia. Dioxygenases / metabolism. Pancreatic Neoplasms / metabolism. Procollagen-Proline Dioxygenase / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenoma, Islet Cell / metabolism. Adenoma, Islet Cell / pathology. Adult. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cell Differentiation. Cell Proliferation. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Hypoxia-Inducible Factor-Proline Dioxygenases. Immunoenzyme Techniques. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Microcirculation. Mixed Function Oxygenases. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / metabolism. Neovascularization, Pathologic. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18927305.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Repressor Proteins; EC 1.- / Mixed Function Oxygenases; EC 1.13.11.- / Dioxygenases; EC 1.14.11.- / HIF1AN protein, human; EC 1.14.11.2 / EGLN1 protein, human; EC 1.14.11.2 / Procollagen-Proline Dioxygenase; EC 1.14.11.29 / EGLN3 protein, human; EC 1.14.11.29 / Hypoxia-Inducible Factor-Proline Dioxygenases
  •  go-up   go-down


47. Hu MG, Zhao GD, Luo Y, Liu R: [Clinical applications of laparoscopic pancreatectomy]. Zhonghua Yi Xue Za Zhi; 2010 Jul 27;90(28):1948-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From March 2003 to February 2010, 49 patients with pancreatic diseases, including 18 males and 31 females with a mean age of (42 ± 14) years old (range: 21 - 77), underwent laparoscopy at our department.
  • The preoperative diagnoses included insulinoma (n = 38), cystadenoma (n = 4), cystadenocarcinoma (n = 1), nonfunctional islet cell tumor (n = 5) and solid-pseudopapillary tumor (n = 1).
  • Secondary operations were needed in 3 cases and pancreatic fistula occurred in 7 cases.
  • CONCLUSION: Laparoscopic pancreatectomy is safe and feasible in the treatment of most benign pancreatic diseases and some malignant tumors.
  • [MeSH-major] Adenoma, Islet Cell / surgery. Laparoscopy. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979855.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C: Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene; 2006 Jan 26;25(4):599-608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations.
  • We used PCR-based subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for beta-catenin.
  • They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Lectins, C-Type / genetics. Lithostathine / genetics. Liver Neoplasms / genetics. Mutation. beta Catenin / genetics
  • [MeSH-minor] Adenoma / genetics. Adult. Cell Line, Tumor. Colonic Neoplasms / genetics. Hepatoblastoma / genetics. Humans. Male. Signal Transduction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314847.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lithostathine; 0 / REG1A protein, human; 0 / beta Catenin; 0 / pancreatitis-associated protein
  •  go-up   go-down


49. Caudill JL, Humphrey SK, Salomão DR: Islet cell tumor of the pancreas: increasing diagnosis after instituting ultrasonography-guided fine needle aspiration. Acta Cytol; 2008 Jan-Feb;52(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Islet cell tumor of the pancreas: increasing diagnosis after instituting ultrasonography-guided fine needle aspiration.
  • OBJECTIVE: To review the clinical and cytomorphologic features of pancreatic islet cell tumors (ICT).
  • STUDY DESIGN: Computer search identified patients with pancreatic ICT diagnosed by fine needle aspiration biopsy (FNAB) between January 1995 and December 2003.
  • Twenty-two patients underwent tumor resection.
  • CONCLUSION: Newer radiography and biopsy techniques to detect and examine smaller pancreatic masses have increased the number of pancreatic ICT diagnoses at our institution.
  • The distinctive cytomorphologic features of pancreatic ICT make it reliably diagnosable by FNAB.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Endosonography. Female. Humans. Islets of Langerhans / pathology. Islets of Langerhans / radiography. Islets of Langerhans / ultrasonography. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323274.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Chen M, Rahman L, Voeller D, Kastanos E, Yang SX, Feigenbaum L, Allegra C, Kaye FJ, Steeg P, Zajac-Kaye M: Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene; 2007 Jul 19;26(33):4817-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas.
  • In addition, TS gene expression has been linked with cell-cycle regulation and cell proliferation through the ability of retinoblastoma protein to repress the transcriptional activation of E2F target genes such as TS.
  • To investigate the role of deregulated TS activity in tumor development, we generated transgenic mice that express high levels of catalytically active human TS (hTS) exclusively in the pancreas and low levels of hTS in multiple other tissues.
  • Analyses of pancreatic tissue in TS transgenic mice revealed abnormalities within the endocrine pancreas, ranging from pancreatic islet hyperplasia to the detection of islet cell tumors.
  • Overexpression of hTS in murine islets provides a new model to study genetic alterations associated with the progression from normal cells to hyperplasia to islet cell tumors, and suggests that this mouse model may be useful for regulating TS activity in vivo for development of cancer prevention and new therapies.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Islets of Langerhans / pathology. Pancreatic Neoplasms / pathology. Thymidylate Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17297449.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


51. Toumpanakis CG, Caplin ME: Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol; 2008 Mar;103(3):729-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are usually sporadic; however, familial (inherited) syndromes, such as the multiple endocrine neoplasia 1 (MEN-1) syndrome, von Hippel-Lindau (VHL) syndrome, neurofibromatosis (NF-1), as well as tuberous sclerosis, may be associated with proximal intestinal and pancreatic NETs.
  • Whether these chromosomic alterations have implications in the treatment of patients and the outcome of the disease is still unclear.
  • [MeSH-major] Gastrointestinal Neoplasms / genetics. Neuroendocrine Tumors / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / genetics. Carcinoid Tumor / diagnosis. Carcinoid Tumor / genetics. Genetic Testing. Humans. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341492.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


52. Dromain C, Baudin E: [Endocrine pancreas]. J Radiol; 2005 Jun;86(6 Pt 2):797-804; quiz 805
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine pancreas].
  • [Transliterated title] Pancréas endocrine.
  • Pancreatic endocrine tumors (PET) are characterised by their hormone synthesis capability and can be associated with an hereditary syndrome-related cancer.
  • The challenge for imaging is to localize the tumor.
  • [MeSH-major] Diagnostic Imaging. Islets of Langerhans / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / diagnosis. Endosonography. Humans. Magnetic Resonance Imaging. Positron-Emission Tomography. Somatostatin. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142073.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


53. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer; 2005 Jan 17;92(1):94-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.
  • Tumour-associated angiogenesis is partly regulated by the hypoxia-inducible factor (HIF) pathway.
  • Endocrine tumours are highly vascularised and the molecular mechanisms of their angiogenesis are not fully delineated.
  • The aim of this study is to evaluate angiogenesis and expression of HIF-related molecules in a series of patients with pancreatic endocrine tumours (PETs).
  • The expression of vascular endothelial growth factor (VEGF), HIF-1alpha, HIF-2alpha and carbonic anhydrase 9 (CA9) was examined by immunohistochemistry in 45 patients with PETs and compared to microvascular density (MVD), endothelial proliferation, tumour stage and survival.
  • Microvascular density was significantly higher in benign PETs than in PETs of uncertain prognosis, well-differentiated and poorly differentiated carcinomas (mean values: 535, 436, 252 and 45 vessels mm(-2), respectively, P < 0.0001).
  • The regulation of HIF signalling appears to be specific in pancreatic endocrine tumours.
  • [MeSH-major] Adenoma, Islet Cell / blood supply. Adenoma, Islet Cell / metabolism. Neovascularization, Pathologic. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / metabolism. Vascular Endothelial Growth Factors / metabolism
  • [MeSH-minor] Adult. Basic Helix-Loop-Helix Transcription Factors. Carbonic Anhydrases / metabolism. Disease Progression. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit. Male. Microcirculation. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Apr;34(5):609-18 [9713263.001]
  • [Cites] Neuroendocrinology. 1986;43(2):159-65 [3523276.001]
  • [Cites] Gut. 1998 Sep;43(3):422-7 [9863490.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1309-16 [9815813.001]
  • [Cites] J Pathol. 1998 Nov;186(3):313-8 [10211122.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):404-10 [9218518.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1388-93 [10728704.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1441-5 [10780524.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):167-71 [11248550.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Nature. 2001 Aug 30;412(6850):877-84 [11528470.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Oct;32(2):177-81 [11550286.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):881-90 [11556841.001]
  • [Cites] Novartis Found Symp. 2001;240:212-25; discussion 225-31 [11727931.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):719-25 [11857345.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1276-82 [11953885.001]
  • [Cites] Semin Cell Dev Biol. 2002 Feb;13(1):29-37 [11969369.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2595-604 [12171890.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):45-53; discussion 54 [12210027.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4961-5 [12414859.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):181-5 [12539172.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):18-27 [12605362.001]
  • [Cites] Histopathology. 2003 May;42(5):482-91 [12713626.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):319-23 [7543771.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1196-200 [7590692.001]
  • [Cites] Mol Endocrinol. 1995 Dec;9(12):1760-70 [8614412.001]
  • [Cites] Genomics. 1996 May 1;33(3):480-7 [8661007.001]
  • [Cites] Histopathology. 1997 Mar;30(3):294-301 [9088964.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1417-23 [9358768.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):286-93 [9495200.001]
  • [Cites] Histopathology. 1998 Feb;32(2):133-8 [9543669.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):329-33 [9578082.001]
  • [Cites] J Pathol. 1998 Feb;184(2):119-22 [9602700.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):133-46 [12957288.001]
  • [Cites] Gastroenterology. 2003 Oct;125(4):1094-104 [14517793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • (PMID = 15558070.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factors; 0 / endothelial PAS domain-containing protein 1; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2361752
  •  go-up   go-down


54. Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N: Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body. Dig Surg; 2008;25(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body.
  • BACKGROUND/AIM: Medial pancreatectomy has been applied as a safe and effective alternative in benign diseases located in the pancreatic neck or body.
  • Four patients required an additional resection of the pancreatic remnant because of a positive surgical margin.
  • Three patients with islet cell tumor and 1 patient with solid pseudopapillary tumor had no malignant disease.
  • Postoperative complications occurred in 6 patients (43%): 5 had pancreatic fistulas and 1 had a gastric ulcer.
  • CONCLUSIONS: A medial pancreatectomy is a safe and effective alternative for the treatment of intraductal papillary mucinous neoplasm, islet cell tumor, or solid pseudopapillary tumor located in the neck or body of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Adenoma, Islet Cell / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292661.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


55. O'Grady HL, Conlon KC: Pancreatic neuroendocrine tumours. Eur J Surg Oncol; 2008 Mar;34(3):324-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic neuroendocrine tumours.
  • Pancreatic neuroendocrine tumours (PET) are rare neoplasms of the pancreas accounting for less than 5% of all primary pancreatic malignancies.
  • Non-functioning PETs are pancreatic tumours with endocrine differentiation but lack a clinical syndrome of hormone hypersecretion.
  • Presentation is related to the mass effect of the tumour with symptoms often non-specific.
  • [MeSH-major] Adenoma, Islet Cell. Carcinoma, Islet Cell. Pancreatic Neoplasms
  • [MeSH-minor] Algorithms. Biomarkers, Tumor. Diagnostic Imaging. Humans. Neoplasm Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17967523.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 74
  •  go-up   go-down


56. Elsayes KM, Narra VR, Abou El Abbass HA, Aly TS, Radwan SM, Chen ZM: Pancreatic tumors: diagnostic patterns by 3D gradient-echo post contrast magnetic resonance imaging with pathologic correlation. Curr Probl Diagn Radiol; 2006 Jul-Aug;35(4):125-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic tumors: diagnostic patterns by 3D gradient-echo post contrast magnetic resonance imaging with pathologic correlation.
  • Magnetic resonance (MR) imaging has considerable potential in characterizing pancreatic masses.
  • Certain features can be used by the radiologist to establish a definitive diagnosis for most pancreatic tumors including ductal adenocarcinoma, islet cell tumors, solid and papillary epithelial neoplasms, micro- and macrocystic adenoma, and metastases.
  • In this article, special emphasis will be placed on the impact of 3D GRE sequence in the diagnosis of pancreatic neoplasms with pathologic correlation.
  • [MeSH-major] Contrast Media. Imaging, Three-Dimensional. Magnetic Resonance Imaging. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16814000.001).
  • [ISSN] 0363-0188
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 37
  •  go-up   go-down


57. Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol; 2005 Feb 10;23(5):939-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic islets, and demonstrated efficacy of antiangiogenic therapies.
  • Pericytes have been revealed as functionally important for tumor neovasculature, using kinase inhibitors targeting their platelet-derived growth factor receptors (PDGFRs).
  • Additionally, vascular endothelial growth factor receptor (VEGFR) inhibitors and metronomic chemotherapy show modest benefit against early- but not late-stage disease.
  • MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.
  • RESULTS: Imatinib, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or VEGFR inhibition.
  • MTD using cyclophosphamide caused transitory regression, but then rapid regrowth, in contrast to metronomic cyclophosphamide plus imatinib, which produced stable disease.
  • The MTD regimen elicited apoptosis of tumor cells but not endothelial cells, whereas the other regimens increased endothelial cell apoptosis concordant with efficacy.
  • CONCLUSION: This study demonstrates a potentially tractable clinical strategy in a stringent preclinical model, wherein standard-of-care chemotherapy is followed by a novel maintenance regimen: PDFGR is targeted to disrupt pericyte support, while metronomic chemotherapy and/or VEGFR inhibitors target consequently sensitized endothelial cells, collectively destabilizing pre-existing tumor vasculature and inhibiting ongoing angiogenesis.
  • [MeSH-minor] Adenoma, Islet Cell / drug therapy. Animals. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Benzamides. Clinical Protocols. Cyclophosphamide / therapeutic use. Disease Models, Animal. Endothelial Cells / drug effects. Imatinib Mesylate. Indoles / administration & dosage. Indoles / therapeutic use. Mice. Mice, Transgenic. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Pyrroles / administration & dosage. Pyrroles / therapeutic use. Remission Induction

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15557593.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Benzamides; 0 / Indoles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; 0 / sunitinib; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


58. Choi EK, Park SH, Kim DY, Kim KW, Byun JH, Lee MG, Ha HK: Unusual manifestations of primary pancreatic neoplasia: Radiologic-pathologic correlation. J Comput Assist Tomogr; 2006 Jul-Aug;30(4):610-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual manifestations of primary pancreatic neoplasia: Radiologic-pathologic correlation.
  • Primary pancreatic lesions may present with unusual features ranging from cystic change in ductal adenocarcinoma and islet cell tumors to ductal communication in solid pseudopapillary and mucinous tumors.
  • Consideration of unusual variations of primary pancreatic neoplasm in the differential diagnosis of solid and cystic pancreatic lesions is necessary for their proper diagnostic work-up and management.
  • We present the rare imaging manifestations and corresponding pathologic correlation of a representative group of primary pancreatic tumors, including pancreatic adenocarcinoma, islet cell tumor, solid pseudopapillary tumor, and serous/mucinous cystic tumors.
  • [MeSH-major] Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / radiography. Contrast Media. Cystadenoma / pathology. Cystadenoma / radiography. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845292.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 14
  •  go-up   go-down


59. Borka K, Kaliszky P, Szabó E, Lotz G, Kupcsulik P, Schaff Z, Kiss A: Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas. Virchows Arch; 2007 May;450(5):549-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas.
  • We aimed to analyze protein and messenger RNA (mRNA) expressions of different CLDNs in human pancreatic endocrine tumors (PET) and ductal adenocarcinomas.
  • Normal acini and ducts showed strong CLDNs 1, -3, -4, and -7 and scattered CLDN 2 protein expressions, while Langerhans islands revealed only CLDN 3 and -7 expressions.
  • CLDN 2 expression was found in the half of ductal adenocarcinomas, while the vast majority of endocrine tumors were negative.
  • CLDN 1, -4, and -7 immunohistochemistry was positive in all adenocarcinomas, whereas endocrine tumors were completely negative for CLDNs 1 and -4.
  • CLDN 3 and -7 proteins were detected in all endocrine tumors, while CLDN 3 in ductal adenocarcinomas was negative.
  • The mRNA expression of CLDNs showed differences between endocrine tumors and ductal adenocarcinomas, similar as found for protein expression.
  • High expressions of CLDN 3 in endocrine tumors and CLDN 4 in ductal carcinomas might attract them as targets for adjuvant therapy.
  • [MeSH-major] Adenoma, Islet Cell / metabolism. Carcinoma, Islet Cell / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Proteins / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Gene Expression. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2006 Jan;448(1):52-8 [16220299.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Pathologe. 2003 Jul;24(4):265-71 [14513272.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):649-56 [16183533.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):195-204 [10508866.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:12-5 [15477709.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):162-9 [15754293.001]
  • [Cites] Diagn Mol Pathol. 2004 Dec;13(4):234-40 [15538114.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10 (13):4427-36 [15240533.001]
  • [Cites] Pancreas. 2004 Mar;28(2):181-90 [15028951.001]
  • [Cites] Genes Cells. 1998 Sep;3(9):569-73 [9813107.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5583-7 [11733531.001]
  • [Cites] J Mol Histol. 2004 Nov;35(8-9):811-22 [15609094.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1539-50 [9647647.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Pancreas. 2006 May;32(4):396-402 [16670622.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):1167-70 [16619519.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Nov;41(5):841-4 [1102552.001]
  • [Cites] Hum Pathol. 2006 May;37(5):555-61 [16647953.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):961-8 [16133365.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):23-9 [16357560.001]
  • [Cites] BMC Cancer. 2006 Jul 12;6:186 [16836752.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):431-45 [15750830.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):460-9 [16439986.001]
  • [Cites] Med Electron Microsc. 2003 Sep;36(3):147-56 [14505058.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):428-34 [16328347.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Pathol Int. 2005 Feb;55(2):63-9 [15693851.001]
  • [Cites] Cancer. 2002 Aug 15;95(4 Suppl):923-7 [12209672.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Oncologist. 2006 Jun;11(6):612-23 [16794240.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1121-5 [16254096.001]
  • [Cites] Hepatogastroenterology. 1998 May-Jun;45(21):855-66 [9684147.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):24-7 [15608508.001]
  • [Cites] Pathol Oncol Res. 2005;11(1):26-31 [15800679.001]
  • (PMID = 17429687.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


60. Wang X, Liang L, Jiang Y: Nine cases of childhood adrenal tumour presenting with hypertension and a review of the literature. Acta Paediatr; 2007 Jun;96(6):930-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nine cases of childhood adrenal tumour presenting with hypertension and a review of the literature.
  • The median tumour weight was 73 g (11-530 g) and the size ranged from 1.5 x 1.5 to 12 x 14 cm2.
  • Pheochromocytoma (n = 2), adrenocortical adenoma (n = 3), adrenocortical carcinoma (n = 1), neuroblastoma (n = 2) and ganglioneuromas (n = 1) were found.
  • In one case, adrenal pheochromocytoma first occurred and non-functioning islet cell tumour successively occurred at pancreas.
  • We report a unique case of adrenal pheochromocytoma followed by the occurrence of non-functioning islet cell tumour.


61. Hamir AN, Kunkle RA, Miller JM, Cutlip RC, Richt JA, Kehrli ME Jr, Williams ES: Age-related lesions in laboratory-confined raccoons (Procyon lotor) inoculated with the agent of chronic wasting disease of mule deer. J Vet Diagn Invest; 2007 Nov;19(6):680-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related lesions in laboratory-confined raccoons (Procyon lotor) inoculated with the agent of chronic wasting disease of mule deer.
  • This communication documents age-associated pathologic changes and final observations on experimental transmission of chronic wasting disease (CWD) by the intracerebral route to raccoons (Procyon lotor).
  • Six years after inoculation, none of the 3 remaining CWD-inoculated raccoons had shown clinical signs of neurologic disorder, and the experiment was terminated.
  • Age-related lesions observed in these raccoons included islet-cell pancreatic amyloidosis (5/6), cystic endometrial hyperplasia (3/4), cerebrovascular mineralization (5/6), neuroaxonal degeneration (3/6), transitional-cell adenoma of the urinary bladder (1/6), and myocardial inclusions (4/6).
  • [MeSH-major] Aging. Deer. Raccoons. Wasting Disease, Chronic / pathology. Wasting Disease, Chronic / transmission

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998557.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prions
  •  go-up   go-down


62. Maser C, Toset A, Roman S: Gastrointestinal manifestations of endocrine disease. World J Gastroenterol; 2006 May 28;12(20):3174-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal manifestations of endocrine disease.
  • The hormonal interactions among the systems throughout the body are not fully understood; many vague clinical symptoms may in fact be manifestations of underlying endocrine diseases.
  • The aim of the following review is to discuss gastrointestinal manifestations of surgically correctable endocrine diseases, focusing on abnormalities of thyroid function, cancer and finally autoimmune diseases.
  • We also review manifestations of pancreatic endocrine tumors, and multiple endocrine neoplasia.
  • [MeSH-major] Endocrine System Diseases / complications. Gastrointestinal Diseases / etiology. Gastrointestinal Tract / physiopathology
  • [MeSH-minor] Adenoma, Islet Cell / complications. Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / physiopathology. Adenoma, Islet Cell / surgery. Humans. Neuroendocrine Tumors / complications. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / physiopathology. Neuroendocrine Tumors / surgery. Thyroid Diseases / complications. Thyroid Diseases / diagnosis. Thyroid Diseases / physiopathology. Thyroid Diseases / surgery

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):286-92 [10634400.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Sep;55(3):357-62 [11589679.001]
  • [Cites] Dig Dis Sci. 2001 Dec;46(12):2631-5 [11768252.001]
  • [Cites] Ann Surg. 2002 May;235(5):648-54; discussion 654-5 [11981210.001]
  • [Cites] Histopathology. 1997 Sep;31(3):231-6 [9354893.001]
  • [Cites] Hepatogastroenterology. 1997 Sep-Oct;44(17):1500-8 [9356880.001]
  • [Cites] Scand J Gastroenterol. 1998 Jan;33(1):88-92 [9489914.001]
  • [Cites] World J Surg. 1998 Jul;22(7):738-42; discussion 743 [9606291.001]
  • [Cites] World J Surg. 1998 Dec;22(12):1231-6 [9841749.001]
  • [Cites] Surgery. 1998 Dec;124(6):1050-5 [9854582.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12):2391-6 [9860398.001]
  • [Cites] Mod Pathol. 1999 Apr;12(4):400-11 [10229505.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):7-9 [10393829.001]
  • [Cites] Arch Surg. 1999 Aug;134(8):818-22; discussion 822-3 [10443803.001]
  • [Cites] Arch Intern Med. 1999 Aug 9-23;159(15):1726-30 [10448775.001]
  • [Cites] N Engl J Med. 1999 Aug 26;341(9):635-44 [10460814.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Nov;229(10):1007-16 [15522836.001]
  • [Cites] World J Surg. 2004 Sep;28(9):886-9 [15593462.001]
  • [Cites] Neth J Med. 2004 Sep;62(8):293-6 [15588071.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1231-8 [15517477.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1239-47 [15517485.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 2005 Aug;106(8):472-8 [16119110.001]
  • [Cites] World J Surg. 2002 Oct;26(10):1291-6 [12205549.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:159-69 [12381551.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Dec;57(6):821-5 [12460333.001]
  • [Cites] Diabetes Care. 2003 Jan;26(1):82-8 [12502662.001]
  • [Cites] Pathology. 2003 Feb;35(1):42-6 [12701683.001]
  • [Cites] Eur Radiol. 2004 May;14(5):923-5 [12955450.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1806-9 [15188511.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):469-72 [15313691.001]
  • [Cites] Dysphagia. 2004 Spring;19(2):120-4 [15382800.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):4944-8 [15472189.001]
  • [Cites] N Engl J Med. 1968 May 9;278(19):1056-8 [5644968.001]
  • [Cites] Ann Intern Med. 1973 May;78(5):669-75 [4711771.001]
  • [Cites] J Clin Gastroenterol. 1984 Oct;6(5):437-40 [6501830.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1986 Jun;87(6):671-9 [3526120.001]
  • [Cites] Ann Surg. 1987 Mar;205(3):230-9 [3548610.001]
  • [Cites] Br J Surg. 1987 May;74(5):377-80 [3036290.001]
  • [Cites] Gastroenterology. 1989 Oct;97(4):911-9 [2777044.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):99-106 [1983854.001]
  • [Cites] Tissue Antigens. 1990 Sep;36(3):136-7 [2278049.001]
  • [Cites] Am J Med. 1992 Feb;92(2):183-8 [1543203.001]
  • [Cites] J Clin Gastroenterol. 1992 Jan;14(1):56-8 [1556409.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Sep;75(3):745-9 [1517363.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):745-50 [8431855.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):101-8 [8382467.001]
  • [Cites] Histopathology. 1994 Dec;25(6):549-61 [7698732.001]
  • [Cites] Ann Intern Med. 1995 Aug 15;123(4):269-73 [7611592.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):611-3 [8813970.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Endocrinol. 1996 Dec;151(3):431-7 [8994388.001]
  • [Cites] Int J Colorectal Dis. 1997;12(4):240-2 [9272455.001]
  • (PMID = 16718836.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 58
  • [Other-IDs] NLM/ PMC4087959
  •  go-up   go-down


63. Ozturk M, Chiu CY, Akdeniz N, Jenq SF, Chang SC, Hsa CY, Jap TS: Two novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1. J Endocrinol Invest; 2006 Jun;29(6):523-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1.
  • Multiple endocrine neoplasia type 1 (MEN1) is characterized by parathyroid, enteropancreatic endocrine and pituitary adenomas as well as germline mutation of the MEN1 gene.
  • This patient presented with a complaint of epigastric pain and watery diarrhea over the past 3 months, and had undergone subtotal parathyroidectomy and enucleation of pancreatic islet cell tumor about 10 yr before.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / genetics. Mutation, Missense. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adenoma / genetics. Adolescent. Adult. Aged. Amino Acid Sequence. Child. Child, Preschool. DNA Mutational Analysis. Female. Humans. Hyperparathyroidism, Primary / genetics. Male. Middle Aged. Parathyroid Neoplasms / genetics. Pituitary Neoplasms / genetics. Prolactinoma / genetics. Taiwan. Turkey

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 1999 Nov;141(5):475-80 [10576763.001]
  • [Cites] Arch Surg. 1991 Aug;126(8):935-52 [1677802.001]
  • [Cites] Hum Mutat. 1999;13(1):54-60 [9888389.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):641-7 [12049533.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5282-93 [11701693.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Jul;59(1):129-35 [12807514.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Mol Endocrinol. 2001 Oct;15(10):1653-64 [11579199.001]
  • [Cites] Endocr Relat Cancer. 1999 Dec;6(4):449-73 [10730900.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Apr;56(4):465-73 [11966739.001]
  • [Cites] Nature. 1988 Mar 3;332(6159):85-7 [2894610.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1177-83 [9215690.001]
  • [Cites] Hum Mol Genet. 1997 Jul;6(7):1169-75 [9215689.001]
  • [Cites] J Endocrinol Invest. 2004 Oct;27(9):878-82 [15648555.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2688-93 [12050235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1630-4 [9465067.001]
  • [Cites] Hum Mutat. 1999;13(3):175-85 [10090472.001]
  • [Cites] Genomics. 1997 Jun 15;42(3):436-45 [9205115.001]
  • [Cites] J Endocrinol Invest. 2002 Jun;25(6):508-12 [12109621.001]
  • [Cites] Hum Mutat. 2002 Jul;20(1):35-47 [12112656.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Mar;62(3):336-42 [15730416.001]
  • (PMID = 16840830.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


64. Zhang TP, Zhao YP, Zhu Y, Cai LX, Cui QC, Chen J: [Clinicopathologic features and surgical treatment of nonfunctioning islet cell tumors (78 case report)]. Zhonghua Yi Xue Za Zhi; 2005 Sep 28;85(37):2647-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic features and surgical treatment of nonfunctioning islet cell tumors (78 case report)].
  • OBJECTIVE: To investigate surgical treatment results and clinical pathological specifics in the treatment of non-functional islet cell tumor.
  • METHODS: To perform retrospective analysis of 78 cases of non-functional islet cell tumor treated at Peking Union Medical College Hospital from July 1968 through January 2005, and summarize clinical symptoms and signs, primary diagnosis before surgery, surgical treatment, pathologic specifics and immuno-histological analysis.
  • Insulin, glucagon, pancreatic polypeptide, somatostatin, vasoactive intestinal peptide and gastrin positive rates are 64.6% (42/65), 47.5% (22/53), 45.8% (22/48), 37.5% (21/56), 23.9% (11/46) and 22.6% (7/31).
  • CONCLUSIONS: Non-functional islet cell tumor lack specificity, Bus and CT are primary examination methods, immuno-histological analysis indicates various different hormones, but lacks the presence of related clinical symptoms.
  • Surgery is an effective form of treatment in the treatment of non-functional islet cell tumor, even with distal metastasis, immediate surgical removal and treatment, extend prognosis.
  • [MeSH-major] Adenoma, Islet Cell / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321328.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. McElroy MK, Lowy AM, Weidner N: Case report: focal nesidioblastosis ("nesidioblastoma") in an adult. Hum Pathol; 2010 Mar;41(3):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: focal nesidioblastosis ("nesidioblastoma") in an adult.
  • Adult nesidioblastosis is an uncommon cause of hyperinsulinemic hypoglycemia characterized by diffuse islet hyperplasia with beta-cell hypertrophy and atypia.
  • In contrast to infants, a focal form of adult nesidioblastosis (ie, "nesidioblastoma") has not been documented, although proposed.
  • [MeSH-major] Nesidioblastosis / pathology. Pancreas / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20004945.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


66. Ekeblad S: Islet cell tumours. Adv Exp Med Biol; 2010;654:771-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Islet cell tumours.
  • Pancreatic endocrine tumours can cause hormonal symptoms by over-secretion of hormones.
  • They are less aggressive than exocrine pancreatic cancer, but carry a variable prognosis.
  • The tumours are either sporadic or hereditary, as part of the multiple endocrine neoplasia type 1 syndrome.
  • Hereditary forms of pancreatic endocrine tumours are caused by mutations in the MEN1 gene.
  • Menin, the protein encoded by this gene, has been shown to interact with numerous transcription factors and proteins involved in cell-cycle control, shedding some light on the importance of the protein.
  • Several advances have been made in prognostication; a tumour-node-metastasis system has been evaluated and seems to have prognostic value, and several new molecular prognostic markers are under evaluation.
  • It is hoped that the tumour-node-metastasis system and other prognostic markers will be adopted in clinical routine and improve prognostication and treatment choices.
  • [MeSH-major] Adenoma, Islet Cell / therapy. Multiple Endocrine Neoplasia Type 1 / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20217524.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones
  • [Number-of-references] 81
  •  go-up   go-down


67. Recaldini C, Carrafiello G, Bertolotti E, Angeretti MG, Fugazzola C: Contrast-enhanced ultrasonograpic findings in pancreatic tumors. Int J Med Sci; 2008;5(4):203-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast-enhanced ultrasonograpic findings in pancreatic tumors.
  • OBJECTIVE: The purpose of this article is to present the potentials and limits of contrast-enhanced ultrasonography (CEUS) in the characterization of pancreatic tumors, usually hypoechoic or cystic at B-mode ultrasound.
  • CONCLUSION: As regards hypoechoic lesions at B-mode ultrasound, CEUS often can distinguish among adenocarcinoma, islet cell tumor and serous microcystic adenoma.
  • [MeSH-major] Contrast Media / chemistry. Pancreas / ultrasonography. Pancreatic Neoplasms / diagnosis. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):367-71 [11461864.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12(26):4181-4 [16830370.001]
  • [Cites] Radiol Med. 2001 Jul-Aug;102(1-2):23-31 [11677434.001]
  • [Cites] Eur Radiol. 2001;11(10):1939-51 [11702126.001]
  • [Cites] Eur Radiol. 2002 Jan;12(1):151-65 [11868093.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):725-30 [12185053.001]
  • [Cites] J Ultrasound Med. 2002 Sep;21(9):983-91 [12216764.001]
  • [Cites] Scand J Gastroenterol. 2002 Nov;37(11):1313-20 [12465731.001]
  • [Cites] Abdom Imaging. 2004 Mar-Apr;29(2):246-58 [15290954.001]
  • [Cites] Gastrointest Radiol. 1991 Winter;16(1):53-61 [1991611.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):144-52 [15654794.001]
  • [Cites] Pancreatology. 2005;5(4-5):398-402 [15985763.001]
  • [Cites] AJR Am J Roentgenol. 2005 Nov;185(5):1193-200 [16247133.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1471-84 [16284129.001]
  • [Cites] Radiology. 2006 Mar;238(3):912-9 [16439566.001]
  • [Cites] Eur Radiol. 2001;11(9):1626-30 [11511881.001]
  • (PMID = 18645620.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2467517
  • [Keywords] NOTNLM ; contrast-enhanced ultrasonography / pancreatic tumors
  •  go-up   go-down


68. Gómez-Pérez FJ, Cuevas-Ramos D, Valdés PA, Aguilar-Salinas CA, Mehta R, Rull JA: Beta-cell adenomas without hyperinsulinemia with use of highly specific insulin radioimmunoassays: case report and review of literature. Endocr Pract; 2010 Jul-Aug;16(4):660-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-cell adenomas without hyperinsulinemia with use of highly specific insulin radioimmunoassays: case report and review of literature.
  • OBJECTIVE: To report a case of a proinsulin-secreting islet cell adenoma in which the diagnosis was obscured by an ultraspecific insulin assay.
  • Magnetic resonance imaging and endoscopic ultrasonography confirmed the presence of a 2.5-cm tumor in the head of the pancreas.
  • A proinsulin-secreting islet cell tumor was diagnosed.
  • Surgical resection of the tumor was successfully accomplished, but diabetes mellitus developed 4 months postoperatively.
  • CONCLUSION: The diagnosis of a hypoglycemia-producing pancreatic adenoma can be missed when an ultraspecific insulin assay is used.
  • [MeSH-major] Insulinoma / blood. Insulinoma / diagnosis. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / diagnosis. Proinsulin / blood

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439243.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 9035-68-1 / Proinsulin
  •  go-up   go-down


69. Dietrich CF: Comments and illustrations regarding the guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS)--update 2008. Ultraschall Med; 2008 Sep;29 Suppl 4:S188-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ductal adenocarcinoma as the most common tumor of the pancreas is typically hypoenhanced compared to the adjacent pancreatic tissue in all phases.
  • Neuroendocrine tumors and serous microcystic adenoma of the pancreas are characterized by hypervascularization appearing typically hyperenhanced during CEUS.
  • [MeSH-minor] Adenoma, Islet Cell / ultrasonography. Carcinoma, Pancreatic Ductal / ultrasonography. Endosonography / standards. Humans. Liver Diseases / ultrasonography. Liver Neoplasms / ultrasonography. Neuroendocrine Tumors / ultrasonography. Pancreatic Diseases / ultrasonography. Pancreatic Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833497.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


70. Bourcier ME, Sherrod A, DiGuardo M, Vinik AI: Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab; 2009 Sep;94(9):3157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases.
  • CONTEXT: Insulinomas are rare tumors of the pancreatic islet cells that produce insulin.
  • At present, streptozotocin is the only approved drug for the treatment of pancreatic islet cell tumors.
  • SETTING AND PATIENT: This report describes a case of an elderly gentleman with a metastatic pancreatic insulinoma and severe hypoglycemia.
  • He remained euglycemic for the past year with no evidence of tumor progression based on Octreoscan.
  • CONCLUSIONS: Rapamycin may provide a useful means of abrogating tumor growth and controlling hypoglycemia in malignant insulinomas by reducing the malignant beta-cell growth and proliferation as well as inhibiting insulin production.
  • [MeSH-major] Adenoma, Islet Cell / drug therapy. Hypoglycemia / drug therapy. Pancreatic Neoplasms / drug therapy. Sirolimus / therapeutic use


71. Lewis RB, Lattin GE Jr, Paal E: Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics; 2010 Oct;30(6):1445-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: radiologic-clinicopathologic correlation.
  • Pancreatic endocrine tumors (PETs) are primarily well-differentiated tumors composed of cells that resemble normal islet cells but that arise from pancreatic ductal cells.
  • Most are sporadic, but some are associated with familial syndromes such as multiple endocrine neoplasia type 1, von Hippel-Lindau syndrome, and neurofibromatosis type 1.
  • At imaging, PETs typically appear as well-defined hypervascular masses, a finding indicative of their rich capillary network.
  • Knowledge of the characteristic clinical, pathologic, and radiologic features of PETs is important in the evaluation and management of patients with a suspected clinical syndrome or a pancreatic mass.
  • [MeSH-major] Diagnostic Imaging. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / epidemiology. Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / epidemiology. Carcinoma, Islet Cell / pathology. Diagnosis, Differential. Humans. Multiple Endocrine Neoplasia Type 1 / pathology. Neurofibromatosis 1 / pathology. Prevalence. von Hippel-Lindau Disease / pathology

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010.
  • (PMID = 21071369.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


72. Cheng Q, Kantz J, Poffenberger G, Powers AC, Gailani D: Factor XI protein in human pancreas and kidney. Thromb Haemost; 2008 Jul;100(1):158-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factor XI protein in human pancreas and kidney.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Feb 27;303(5662):1378-81 [14988562.001]
  • [Cites] Dig Dis Sci. 1983 Nov;28(11):967-70 [6628156.001]
  • [Cites] Biochemistry. 1986 May 6;25(9):2417-24 [3636155.001]
  • [Cites] Transplantation. 1995 Apr 15;59(7):1060-3 [7709446.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):29023-8 [8910554.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1055-64 [9242536.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1779-84 [12031965.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):5246-57 [16377800.001]
  • [Cites] Thromb Haemost. 2007 Jul;98(1):84-9 [17597996.001]
  • [Cites] Biol Chem. 2007 Sep;388(9):957-63 [17696780.001]
  • [Cites] N Engl J Med. 2000 Mar 9;342(10):696-701 [10706899.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18510-6 [11891231.001]
  • [Cites] Hum Pathol. 1997 Nov;28(11):1295-8 [9385936.001]
  • (PMID = 18612554.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL58837; United States / NIDDK NIH HHS / DK / P60 DK020593; United States / NHLBI NIH HHS / HL / HL058837-12; United States / NIDDK NIH HHS / DK / DK69603; United States / NHLBI NIH HHS / HL / R01 HL081326-01A2; United States / NIDDK NIH HHS / DK / DK 66636; United States / NIDDK NIH HHS / DK / R21 DK068854; United States / NHLBI NIH HHS / HL / HL081326-01A2; United States / NHLBI NIH HHS / HL / R01 HL058837-10; United States / NIDDK NIH HHS / DK / R33 DK066636; United States / NHLBI NIH HHS / HL / R01 HL058837; United States / NIDDK NIH HHS / DK / P30 DK020593; United States / NHLBI NIH HHS / HL / HL058837-10; United States / NIDDK NIH HHS / DK / R01 DK069603; United States / NHLBI NIH HHS / HL / R01 HL058837-11; United States / NIDDK NIH HHS / DK / DK20593; United States / NHLBI NIH HHS / HL / HL058837-09; United States / NHLBI NIH HHS / HL / R01 HL058837-09; United States / NHLBI NIH HHS / HL / R01 HL058837-12; United States / NIDDK NIH HHS / DK / R21 DK066636; United States / NHLBI NIH HHS / HL / HL058837-11; United States / NHLBI NIH HHS / HL / R01 HL081326
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 9013-55-2 / Factor XI
  • [Other-IDs] NLM/ NIHMS98892; NLM/ PMC2690650
  •  go-up   go-down


73. Goh BK, Tan YM, Kumarasinghe MP, Ooi LL: Synchronous serous cystadenoma and pancreatic endocrine tumor: a case report and literature review. Dig Dis Sci; 2006 Feb;51(2):422-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous serous cystadenoma and pancreatic endocrine tumor: a case report and literature review.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):766-75 [2669541.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Gastroenterol Clin Biol. 1993;17(12):968-71 [8125232.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):43-55 [10721806.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2099-105 [6181862.001]
  • [Cites] Arch Surg. 1978 Apr;113(4):512-9 [637722.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):45-53; discussion 54 [12210027.001]
  • [Cites] Br J Radiol. 2000 Jan;73(865):83-6 [10721327.001]
  • [Cites] J Clin Gastroenterol. 2001 May-Jun;32(5):441-3 [11319320.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):800-2 [11064680.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] N Engl J Med. 1982 Mar 11;306(10):580-90 [6120456.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1369-72 [14521452.001]
  • [Cites] J Korean Med Sci. 1997 Oct;12(5):469-72 [9364309.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):317-21 [11141506.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):352-5 [2157344.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):471-5 [8604814.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1248-60 [15517487.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1766-70 [6089999.001]
  • [Cites] AJR Am J Roentgenol. 1994 May;162(5):1091-4 [8165988.001]
  • [Cites] Am J Clin Pathol. 1978 Mar;69(3):289-98 [637043.001]
  • (PMID = 16534691.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


74. Chen G, A J, Wang M, Farley S, Lee LY, Lee LC, Sawicki MP: Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol Cancer Res; 2008 Dec;6(12):1894-907
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Menin promotes the Wnt signaling pathway in pancreatic endocrine cells.
  • Menin is a tumor suppressor protein mutated in patients with multiple endocrine neoplasia type 1.
  • We show that menin is essential for canonical Wnt/beta-catenin signaling in cultured rodent islet tumor cells.
  • Likewise, multiple endocrine neoplasia type 1 disease associated missense mutations of menin abrogate the ability to increase TCF reporter gene activity.
  • Based on these studies, we hypothesized that Wnt signaling could inhibit islet cell proliferation because loss of menin function is thought to increase endocrine tumor cell proliferation.
  • TGP61 rodent islet tumor cells treated with a glycogen synthase kinase 3beta inhibitor that increases Wnt pathway signaling had decreased cell proliferation compared with vehicle-treated cells.
  • Collectively, these data suggest that menin has an essential role in Wnt/beta-catenin signaling through a mechanism that eventually affects histone trimethylation of the downstream target gene Axin2, and activation of Wnt/beta-catenin signaling inhibits islet tumor cell proliferation.
  • [MeSH-major] Adenoma, Islet Cell / metabolism. Multiple Endocrine Neoplasia Type 1 / metabolism. Pancreatic Neoplasms / metabolism. Proto-Oncogene Proteins / metabolism. Wnt Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074834.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 095148
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AXIN2 protein, human; 0 / Axin Protein; 0 / Axin2 protein, mouse; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / Histones; 0 / MEN1 protein, human; 0 / Men1 protein, mouse; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / TCF3 protein, human; 0 / TCF4 protein, human; 0 / Transcription Factors; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


75. Minni F: [Surgical treatment of pancreatic neoplasms]. G Chir; 2008 Apr;29(4):133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of pancreatic neoplasms].
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Pancreatic Ductal / surgery. Humans. Pancreatic Cyst / surgery. Practice Guidelines as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419975.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Editorial; Review
  • [Publication-country] Italy
  • [Number-of-references] 48
  •  go-up   go-down


76. Peranteau WH, Bathaii SM, Pawel B, Hardy O, Alavi A, Stanley CA, Adzick NS: Multiple ectopic lesions of focal islet adenomatosis identified by positron emission tomography scan in an infant with congenital hyperinsulinism. J Pediatr Surg; 2007 Jan;42(1):188-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple ectopic lesions of focal islet adenomatosis identified by positron emission tomography scan in an infant with congenital hyperinsulinism.
  • Congenital hyperinsulinism (HI) exists in 2 histologic forms, focal and diffuse, and rarely has been attributed to lesions in ectopic pancreatic tissue.
  • We present a case of HI resulting from focal pancreatic and ectopic pancreatic lesions.
  • Surgical exploration found pancreatic rests in the jejunum responsible for the hot spots seen on PET.
  • Pathology confirmed the presence of focal HI lesions in the pancreatic head and small intestinal specimens.
  • This case supports the ability of ectopic pancreatic tissue to contribute to the pathology of HI.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Congenital Hyperinsulinism / diagnosis. Jejunal Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis


77. Hofer MD, Chang MC, Hirko KA, Rubin MA, Nosé V: Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Mod Pathol; 2009 Jul;22(7):933-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors.
  • Pancreatic endocrine tumors are rare tumors with unpredictable clinical behavior.
  • No histological features or immunohistochemical markers reliably predict malignant progression and the molecular basis of progression of pancreatic endocrine tumors remains unknown.
  • The metastasis-associated gene 1 is thought to play a role in transcription repression and estrogen receptor interaction and is overexpressed in several human cancers, including endocrine neoplasms.
  • The purpose of this study was to analyze the expression of metastasis-associated gene 1 in pancreatic endocrine tumors for its possible role in malignant progression.
  • Twenty-seven pancreatic endocrine tumors were identified from our archive.
  • The clinical follow-up data were examined and tumors were classified according to the 2004 World Health Organization criteria as benign behavior (WHO 1.1), uncertain behavior (WHO 1.2), well-differentiated endocrine carcinoma (WHO 2), and poorly differentiated endocrine carcinoma (WHO 3).
  • Metastasis-associated gene 1 expression was significantly higher in malignant tumors (n=17) with a mean staining intensity of 3.8 compared with 2.9 in benign tumors (n=10, P=0.046).
  • The expression levels were significantly associated with WHO class (P=0.028), as well as size of tumor (P=0.029), and mitotic rate (P=0.035).
  • We show that metastasis-associated gene 1 expression is significantly associated with malignant behavior in pancreatic endocrine tumors.
  • This may suggest a potential role for metastasis-associated gene 1 in the malignant progression and metastasis and its use as biomarker for malignant pancreatic endocrine tumors.
  • [MeSH-major] Adenoma, Islet Cell / enzymology. Carcinoma, Islet Cell / enzymology. Histone Deacetylases / metabolism. Islets of Langerhans / enzymology. Pancreatic Neoplasms / enzymology. Repressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377441.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


78. Chetty R, Ezzat S, Asa SL: Microadenomatosis of the pancreas in von Hippel-Lindau disease. Am J Surg Pathol; 2006 Dec;30(12):1630; author reply 1630-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microadenomatosis of the pancreas in von Hippel-Lindau disease.
  • [MeSH-major] Adenoma, Islet Cell / complications. Multiple Endocrine Neoplasia Type 1 / complications. Pancreatic Neoplasms / complications. von Hippel-Lindau Disease / complications
  • [MeSH-minor] DNA Mutational Analysis. Genetic Predisposition to Disease. Humans. Mutation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2006 May;30(5):560-74 [16699310.001]
  • (PMID = 17122523.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


79. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol; 2008 Jan;129(1):81-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Even though the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on fine-needle aspiration biopsy (FNAB) specimens have been well defined, a diagnostic challenge is still present.
  • We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in 58 cases of FNAB specimens of the pancreas.
  • The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.
  • S100P is a sensitive and specific marker for the detection of PDA on FNAB specimens on cell-block and smear preparations.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089492.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human
  •  go-up   go-down


80. Ballester MM, Pastor BF, Pascual H, Pallares JT, Albasini JL: [Nesidioblastosis as a cause of hyperinsulinism in the adult]. Cir Esp; 2010 Dec;88(6):423-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nesidioblastosis como causa de hiperinsulinismo en el adulto.
  • [MeSH-major] Adenoma, Islet Cell / complications. Hyperinsulinism / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20494345.001).
  • [ISSN] 1578-147X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


81. Ishikawa T, Itoh A, Kawashima H, Ohno E, Matsubara H, Itoh Y, Nakamura Y, Nakamura M, Miyahara R, Hayashi K, Ishigami M, Katano Y, Ohmiya N, Goto H, Hirooka Y: Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc; 2010 May;71(6):951-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors.
  • BACKGROUND: Pancreatic endocrine tumors (PETs) develop in relatively few patients, but they are often difficult to diagnose because of their small size and various clinical symptoms.
  • OBJECTIVE: The aim of this study was to investigate the usefulness of EUS combined with contrast enhancement (CE-EUS) in the preoperative localization of PETs and the differentiation between malignant and benign PETs.
  • [MeSH-major] Pancreas / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Adenoma, Islet Cell / pathology. Adenoma, Islet Cell / ultrasonography. Adult. Aged. Carcinoma, Islet Cell / pathology. Carcinoma, Islet Cell / ultrasonography. Contrast Media. Diagnosis, Differential. Endosonography. Female. Humans. Male. Middle Aged. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / ultrasonography. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20438884.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


82. Izbizky G, Elias D, Gallo A, Farias P, Sod R: Prenatal diagnosis of fetal bilateral adrenal carcinoma. Ultrasound Obstet Gynecol; 2005 Nov;26(6):669-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postmortem histological findings included nesidioblastosis, (i.e. hyperplasia of the cells of the islets of Langerhans) and adrenocortical cytomegaly, suggestive of a form of Beckwith-Wiedemann syndrome.
  • [MeSH-minor] Abortion, Spontaneous. Adenoma, Islet Cell / pathology. Adult. Diagnosis, Differential. Fatal Outcome. Female. Gestational Age. Humans. Infant, Newborn. Neoplasm Metastasis / pathology. Pancreatic Neoplasms / pathology. Pregnancy. Ultrasonography, Doppler, Color. Ultrasonography, Prenatal / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 ISUOG
  • (PMID = 16254889.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Guardado-Mendoza R, Dick EJ Jr, Jimenez-Ceja LM, Davalli A, Chavez AO, Folli F, Hubbard GB: Spontaneous pathology of the baboon endocrine system. J Med Primatol; 2009 Dec;38(6):383-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous pathology of the baboon endocrine system.
  • BACKGROUND: Study of endocrine pathology in animal models is critical to understanding endocrine pathology in humans.
  • METHODS: We evaluated 434 endocrine-related diagnoses from 4619 baboon necropsies, established the incidence of spontaneous endocrine pathology, and analyzed the clinical and biochemical data associated with the individual cases.
  • RESULTS: The most common diagnoses in descending order, were pancreatic islet cell amyloidosis (n = 259), ovarian cysts (n = 50), pituitary adenoma (n = 37), pancreatic islet cell adenoma (n = 20), granulosa cell tumor (n = 15), thyroid adenoma (n = 11), adrenal hyperplasia (n = 10), thyroid carcinoma (n = 8), and pheochromocytoma (n = 6).
  • The incidence of pancreatic islet cell amyloidosis progressively increased with age.
  • The incidence of pancreatic islet cell amyloidosis and adrenal pathology was similar to humans; the incidence of pituitary adenoma and thyroid pathology was lower than in humans.
  • CONCLUSIONS: Endocrine disease in baboons is common and shares clinical and biochemical characteristics with endocrine disease in humans.
  • [MeSH-major] Endocrine System Diseases / veterinary. Monkey Diseases / epidemiology. Papio

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Primatol. 2007 Apr;36(2):61-79 [17493137.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Sep;34(3):677-705, x [16085166.001]
  • [Cites] Endocr Rev. 2008 May;29(3):303-16 [18314421.001]
  • [Cites] Gynecol Endocrinol. 2008 Aug;24(8):423-7 [18850378.001]
  • [Cites] Am J Clin Pathol. 2000 Feb;113(2):295-302 [10664633.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):245-91 [10857554.001]
  • [Cites] Aust N Z J Med. 2000 Dec;30(6):648-52 [11198571.001]
  • [Cites] Endocr Relat Cancer. 2001 Dec;8(4):287-305 [11733226.001]
  • [Cites] J Med Primatol. 2002 Apr;31(2):84-90 [12110051.001]
  • [Cites] Obes Res. 2003 Jan;11(1):75-80 [12529488.001]
  • [Cites] Comp Med. 2002 Dec;52(6):563-7 [12540172.001]
  • [Cites] J Med Primatol. 2003 Feb;32(1):48-56 [12733602.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] Minerva Ginecol. 2004 Feb;56(1):41-51 [14973409.001]
  • [Cites] Mayo Clin Proc. 1983 Dec;58(12):802-4 [6645626.001]
  • [Cites] Vet Pathol. 1985 Mar;22(2):141-6 [3984159.001]
  • [Cites] Lab Anim Sci. 1986 Oct;36(5):529-33 [3534445.001]
  • [Cites] Acta Med Scand. 1986;220(3):225-32 [3776697.001]
  • [Cites] Clin Chem. 1992 Apr;38(4):486-92 [1568311.001]
  • [Cites] Lab Anim Sci. 1993 Jun;43(3):236-43 [8355484.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):254-74 [15644784.001]
  • [Cites] N Engl J Med. 2005 Jun 9;352(23):2376-8 [15944422.001]
  • [Cites] Diabetes. 2008 Apr;57(4):899-908 [18174524.001]
  • (PMID = 19793179.001).
  • [ISSN] 1600-0684
  • [Journal-full-title] Journal of medical primatology
  • [ISO-abbreviation] J. Med. Primatol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR016228; United States / NCRR NIH HHS / RR / P51 RR013986; United States / NCRR NIH HHS / RR / P51 RR013986-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Other-IDs] NLM/ NIHMS145553; NLM/ PMC2783813
  •  go-up   go-down


84. Long KB, Srivastava A, Hirsch MS, Hornick JL: PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol; 2010 May;34(5):723-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
  • PAX (paired box) genes encode a family of transcription factors that regulate organogenesis and cell-lineage specification in multiple organ systems.
  • In the pancreas, PAX proteins play a critical role in islet cell differentiation.
  • We recently observed that islet cells show strong, diffuse staining for PAX8 by immunohistochemistry.
  • However, PAX8 expression has not previously been examined in pancreatic endocrine tumors (PETs).
  • Expression of PAX8 was significantly associated with WHO category 1.1 ("benign" behavior) compared with category 1.2 (uncertain behavior) or 2 (well-differentiated endocrine carcinoma) (positive in 100%, 64%, and 52% of tumors, respectively; P<0.05).
  • In summary, PAX8 is expressed in normal pancreatic islet cells and in a high proportion of primary and metastatic PETs.
  • PAX8 immunostaining may be helpful in determining the primary site for a WDNET metastatic to the liver, as ileal (PAX8 negative) and pancreatic (PAX8 positive) tumors most often present as a metastasis from an occult primary.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoid Tumor / pathology. Carcinoma, Islet Cell / secondary. Gastrointestinal Neoplasms / pathology. Lung Neoplasms / pathology. Paired Box Transcription Factors / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymph Nodes / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Dec;35(12):1906-8 [22067332.001]
  • (PMID = 20414099.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


85. Sakurai A, Katai M, Yamashita K, Mori J, Fukushima Y, Hashizume K: Long-term follow-up of patients with multiple endocrine neoplasia type 1. Endocr J; 2007 Apr;54(2):295-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients with multiple endocrine neoplasia type 1.
  • Whether early surgical treatment of non-functioning pancreas islet cell tumor (NFPT) provides a favorable quality of life and life expectancy in patients with multiple endocrine neoplasia type 1 (MEN1) remains controversial.
  • [MeSH-major] Adenoma, Islet Cell / etiology. Adenoma, Islet Cell / surgery. Multiple Endocrine Neoplasia Type 1 / complications. Pancreatic Neoplasms / etiology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Asian Continental Ancestry Group. Diabetes Mellitus / etiology. Disease Progression. Female. Follow-Up Studies. Glucose Intolerance / etiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasms, Second Primary / radiography. Pancreas / physiopathology. Pancreatectomy / adverse effects. Pancreatectomy / methods. Tomography, X-Ray Computed


86. Varker KA, Campbell J, Shah MH: Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol; 2008 Apr;61(4):661-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
  • PURPOSE: Carcinoid and islet cell tumors are known to be highly vascular.
  • There is no effective systemic therapy currently available for metastatic disease.
  • Tumor response was assessed at 12-week intervals using RECIST criteria.
  • Planned treatment duration was 24 weeks unless unacceptable toxicity or disease progression was observed.
  • Best response was stable disease (SD) in 11 of 16 response-evaluable patients (69%).
  • CONCLUSIONS: Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses.
  • [MeSH-major] Adenoma, Islet Cell / drug therapy. Angiogenesis Inhibitors / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / secondary. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / secondary. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pancreatic Hormones / blood. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589846.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones; 106477-83-2 / pancreastatin; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


87. Fernando HS, Hawkyard SJ, Poon P, Musa M: Renal cell carcinoma with non-islet cell tumor hypoglycemia. Int J Urol; 2006 Jul;13(7):985-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma with non-islet cell tumor hypoglycemia.
  • We report a case of an elderly gentleman with renal cell carcinoma presenting with the rare entity of non-islet cell tumor hypoglycemia (NICTH).
  • Non-islet cell tumor hypoglycemia syndrome is caused by the tumor producing insulin-like growth factor II, causing hypoglycemia.
  • [MeSH-major] Adenoma, Islet Cell / complications. Carcinoma, Renal Cell / complications. Hypoglycemia / etiology. Kidney Neoplasms / complications. Pancreatic Neoplasms / complications


88. Jabbour SA, Davidovici BB, Wolf R: Rare syndromes. Clin Dermatol; 2006 Jul-Aug;24(4):299-316
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatologists may also encounter patients presenting with skin lesions that reflect an underlying endocrine disorder not commonly seen in daily practice.
  • Some of these endocrine disorders include glucagonoma, neurofibromatosis type 1, McCune-Albright syndrome, multiple endocrine neoplasia, the Carney complex, carcinoid tumors, and mastocytosis.
  • McCune-Albright syndrome is characterized by café-au-lait spots, polyostotic fibrous dysplasia, sexual precocity, and hyperfunction of multiple endocrine glands.
  • Multiple endocrine neoplasia type 2A is characterized by medullary thyroid cancer, pheochromocytoma, and primary parathyroid hyperplasia.
  • In some patients with multiple endocrine neoplasia type 2A, cutaneous lichen amyloidosis may also be present.
  • Multiple endocrine neoplasia type 2B is characterized by medullary thyroid cancer and pheochromocytoma but not hyperparathyroidism.
  • Multiple endocrine neoplasia type 1 is an autosomal dominant predisposition to tumors of the parathyroid glands (four-gland hyperplasia), anterior pituitary, and pancreatic islet cells; hence, the mnemonic device of the "3 Ps"; multiple cutaneous lesions (angiofibromas and collagenomas) are frequent in patients with multiple endocrine neoplasia type 1.
  • Carney complex may be viewed as a form of multiple endocrine neoplasia because affected patients often have tumors of two or more endocrine glands, including primary pigmented nodular adrenocortical disease (some with Cushing's syndrome), pituitary adenoma, testicular neoplasms, thyroid adenoma or carcinoma, and ovarian cysts.
  • Additional unusual manifestations include psammomatous melanotic schwannoma, breast ductal adenoma, and a rare bone tumor, osteochondromyxoma.
  • Mast cell diseases include all disorders of mast cell proliferation.
  • [MeSH-major] Endocrine System Diseases / genetics. Endocrine System Diseases / pathology. Mastocytosis, Cutaneous / pathology. Multiple Endocrine Neoplasia / genetics. Multiple Endocrine Neoplasia / pathology

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828412.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 155
  •  go-up   go-down


89. Hoff AO, Hauache OM: [Multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical and molecular diagnosis and treatment of the associated disturbances]. Arq Bras Endocrinol Metabol; 2005 Oct;49(5):735-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical and molecular diagnosis and treatment of the associated disturbances].
  • [Transliterated title] Neoplasia endócrina múltipla tipo 1: diagnóstico clínico, laboratorial e molecular e tratamento das doenças associadas.
  • Multiple endocrine neoplasia (MEN) syndromes include types 1 (MEN 1) and 2 (MEN 2), von Hippel-Lindau syndrome, neurofibromatosis type 1 and Carney complex.
  • These are complex genetic syndromes caused by activation or inactivation of different types of genes known to be involved in the regulation of cell proliferation.
  • MEN 1 is a hereditary syndrome, transmitted in an autosomic dominant fashion and caused by an inactivating mutation of the MEN 1 gene, characterized by the development of primary hyperparathyroidism, islet cell tumors and pituitary adenomas.
  • In addition, these patients can present with cutaneous manifestations such as angiofibromas and collagenomas, and can develop other neoplastic manifestations including carcinoids, thyroid tumors, adrenal adenomas, lipomas, pheochromocytomas and meningiomas.
  • The MEN 1 gene encodes a peptide which is a tumor suppressor gene called menin.
  • Several studies have demonstrated its importance in regulation of cell proliferation and have confirmed its role in the pathogenesis of the MEN 1 syndrome.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1. Mutation / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / genetics. Adenoma, Islet Cell / therapy. Genetic Testing. Humans. Hyperparathyroidism, Primary / diagnosis. Hyperparathyroidism, Primary / genetics. Hyperparathyroidism, Primary / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / genetics. Pituitary Neoplasms / therapy


90. Izumiyama H, Gotyo N, Fukai N, Ozawa N, Doi M, Yoshimoto T, Arii S, Hirata Y: Glucose-responsive and octreotide-sensitive insulinoma. Intern Med; 2006;45(8):519-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although MRI and CT scan of the abdomen failed to detect any mass lesions in the pancreas, Octreoscan revealed increased radioactive uptake around the pancreatic head region.
  • At surgery, two islet cell adenomas were identified in the pancreas and resected.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Glucose Tolerance Test. Insulinoma / drug therapy. Octreotide / therapeutic use. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702744.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Blood Glucose; 0 / Insulin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


91. Kanzaki M, Kashihara H, Kiura K, Murakami K, Iwagaki H, Wada J, Makino H: Severe hypoglycemia induced by IGF-II producing non-islet cell tumor. Intern Med; 2007;46(13):1061
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypoglycemia induced by IGF-II producing non-islet cell tumor.
  • [MeSH-major] Adenoma, Islet Cell / complications. Hypoglycemia / etiology. Insulin-Like Growth Factor II / metabolism. Pancreatic Neoplasms / complications

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603253.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


92. Desai AA, McGuigan JE, Draganov P: Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor. Int J Gastrointest Cancer; 2005;35(2):157-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor.
  • Patients with the Zollinger-Ellison syndrome are characterized by islet-cell tumors, striking gastric acid hypersecretion, and peptic ulcer disease.
  • It is a rare syndrome caused by non-beta cell islet-cell tumors (gastrinomas) located in or in proximity to the pancreas.
  • Exuberant secretion of gastrin from the gastrinomas produces severe gastric acid hypersecretion that often leads to impressive peptic ulcer disease and the constellation of symptoms listed above.
  • We describe a patient presenting with clinical manifestations characteristic of the ZES with strikingly elevated gastric acid secretion,multiple ulcers in the first and second portions of the duodenum and diarrhea, but in absence of islet-cell tumor and/or hypergastrinemia.
  • [MeSH-minor] Adenoma, Islet Cell. Gastrins / blood. Humans. Male. Middle Aged. Pancreatic Neoplasms. Phenotype

  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2003 Feb;98(2):301-7 [12591045.001]
  • [Cites] Ann Intern Med. 1984 Jul;101(1):7-13 [6145381.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1129-35 [9322507.001]
  • [Cites] Int J Pancreatol. 1996 Apr;19(2):79-91 [8723550.001]
  • [Cites] Q J Med. 1983 Spring;52(206):256-67 [6137024.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):195-8 [3131179.001]
  • [Cites] Gastroenterology. 1973 Jul;65(1):140-65 [4354624.001]
  • [Cites] Gastroenterology. 1988 Sep;95(3):657-67 [3396814.001]
  • [Cites] Ann Surg. 1987 May;205(5):550-6 [3579402.001]
  • [Cites] Ann Surg. 1955 Oct;142(4):709-23; discussion, 724-8 [13259432.001]
  • [Cites] N Engl J Med. 1968 Jun 13;278(24):1308-13 [5648596.001]
  • [Cites] Gastroenterology. 1980 Dec;79(6):1324-31 [7439637.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4682-6 [9354421.001]
  • [Cites] Ann Intern Med. 1985 Aug;103(2):215-7 [4014903.001]
  • [Cites] Curr Probl Surg. 1994 Feb;31(2):77-156 [7904550.001]
  • [Cites] Ann Intern Med. 1989 Nov 1;111(9):713-22 [2572194.001]
  • [Cites] Ann Intern Med. 1977 Dec;87(6):680-6 [931203.001]
  • [Cites] Dig Dis Sci. 1991 Oct;36(10):1371-6 [1914757.001]
  • (PMID = 15879632.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


93. Liu R, Hu MG, Luo Y: [Laparoscopic resection of pancreatic islet cell tumors]. Zhonghua Wai Ke Za Zhi; 2008 Dec 1;46(23):1768-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic resection of pancreatic islet cell tumors].
  • OBJECTIVE: To summarize the surgical technique and clinical experience of total laparoscopic resection of the pancreatic islet cell tumors.
  • METHODS: From July 2002 to December 2007, 30 cases including 12 males and 18 females were diagnosed as pancreatic islet cell tumor.
  • Pancreatic leakage occurred in 3 cases, 2 of which were cured conservatively.
  • And the other one were cured by endoscopic retrograde cannulation of the pancreatic duct.
  • CONCLUSION: Total laparoscopic resection is a safe and effective method for pancreatic islet cell tumors.
  • [MeSH-major] Adenoma, Islet Cell / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094778.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Noone TC, Hosey J, Firat Z, Semelka RC: Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab; 2005 Jun;19(2):195-211
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and localization of islet-cell tumours of the pancreas on CT and MRI.
  • Islet-cell tumours are neuroendocrine tumours that arise from the endocrine pancreas.
  • They range from benign to malignant.
  • Multiphase, post-contrast series are commended for the evaluation of islet-cell tumours with either modality.
  • [MeSH-major] Adenoma, Islet Cell / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Gastrinoma / diagnosis. Humans. Insulinoma / diagnosis. Islets of Langerhans / pathology. Multiple Endocrine Neoplasia Type 1 / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763695.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  •  go-up   go-down


95. Frankel WL: Update on pancreatic endocrine tumors. Arch Pathol Lab Med; 2006 Jul;130(7):963-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on pancreatic endocrine tumors.
  • Endocrine tumors of the pancreas represent 1% to 2% of all pancreatic neoplasms.
  • The morphologic spectrum of these tumors can be variable, and the differential diagnosis includes chronic pancreatitis with neuroendocrine hyperplasia, ductal adenocarcinoma, solid pseudopapillary tumor, acinar cell carcinoma, and pancreatoblastoma.
  • It is important to be aware that unusual morphologic variants of pancreatic endocrine tumors are common, and immunohistochemical stains can help avoid misdiagnosis.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Carcinoma, Islet Cell / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Diagnosis, Differential. Humans. Islets of Langerhans / pathology. Neoplasms, Germ Cell and Embryonal / diagnosis. Pancreatitis, Chronic / diagnosis. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831051.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


96. Swain JM, Adams RB, Farnell MB, Que FG, Sarr MG: Gastric and pancreatoduodenal resection for malignant lesions after previous gastric bypass--diagnosis and methods of reconstruction. Surg Obes Relat Dis; 2010 Nov-Dec;6(6):670-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the available patients, 7 were identified with 2 remnant gastric cancers (2 signet ring cell adenocarcinomas), 4 pancreatic neoplasms (2 adenocarcinomas and 2 neuroendocrine cancers), and 1 ampullary cancer.
  • The pancreatic and duodenal neoplasms required pancreatoduodenectomy, with 4 of 5 patients also undergoing remnant gastrectomy.
  • The patients after pancreatoduodenectomy required biliary and pancreatic reconstruction with the pancreaticobiliary limb, Roux limb, or proximal common channel, depending on the limb length.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Duodenal Neoplasms / surgery. Gastrectomy / methods. Gastric Bypass. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / epidemiology. Adenoma, Islet Cell / surgery. Aged. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / epidemiology. Carcinoma, Neuroendocrine / surgery. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / epidemiology. Common Bile Duct Neoplasms / surgery. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20627707.001).
  • [ISSN] 1878-7533
  • [Journal-full-title] Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • [ISO-abbreviation] Surg Obes Relat Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Rothenstein J, Cleary SP, Pond GR, Dale D, Gallinger S, Moore MJ, Brierley J, Siu LL: Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol; 2008 Feb;31(1):64-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological distribution demonstrated that 72% were NET/carcinoids, 21% were islet cell tumors, and 6% were small cell carcinomas.
  • At presentation, 53% of patients had distant metastases and 46% had loco-regional disease.
  • [MeSH-major] Adenoma, Islet Cell / therapy. Carcinoid Tumor / therapy. Carcinoma, Small Cell / therapy. Gastrointestinal Neoplasms / therapy. Neuroendocrine Tumors / therapy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376230.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


98. Roggin KK, Rudloff U, Blumgart LH, Brennan MF: Central pancreatectomy revisited. J Gastrointest Surg; 2006 Jun;10(6):804-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This limited resection has the advantage of conserving normal, uninvolved pancreatic parenchyma, thus reducing the possibility of postoperative exocrine and endocrine dysfunction.
  • While the incidence of postoperative endocrine insufficiency may be as low as 4%, procedural morbidity, specifically pancreatic fistula, appears to exceed the published rates for standard resections (i.e., distal/subtotal pancreatectomy or pancreaticoduodenectomy).
  • We have reviewed our prospective pancreatic cancer database to determine the utilization of central pancreatectomy in a major cancer center with expertise in pancreatic surgery.
  • Six (60%) had postoperative complications including three cases (30%) of pancreatic fistula.
  • At a median follow-up of 13.6 months (mean, 25.2 months), only one patient had mild endocrine insufficiency and no patients had clinically significant exocrine dysfunction.
  • The associated morbidity of central pancreatectomy may outweigh any potential benefit in long-term pancreatic secretory function.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / surgery. Cystadenoma, Serous / surgery. Humans. Pancreatic Fistula / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 May;229(5):693-8; discussion 698-700 [10235528.001]
  • [Cites] Ann Surg. 1989 Mar;209(3):273-8 [2923514.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):266-71 [15864637.001]
  • [Cites] Surgery. 1984 Oct;96(4):608-16 [6435270.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):57-65 [12496531.001]
  • [Cites] Hepatogastroenterology. 1995 Sep-Oct;42(5):730-3 [8751242.001]
  • [Cites] World J Surg. 2003 May;27(5):595-8 [12715230.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):898-903 [2179721.001]
  • [Cites] Am J Surg. 2002 Jan;183(1):42-52 [11869701.001]
  • [Cites] Ann Surg. 2002 Nov;236(5):612-8 [12409667.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):223-8 [15720996.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):871-6 [15194067.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Surgery. 1993 May;113(5):532-5 [8488471.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):803-13 [12035036.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):580-8; discussion 588-92 [7574936.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):403-13 [1015887.001]
  • [Cites] J Surg Oncol. 2001 Jun;77(2):132-5 [11398167.001]
  • [Cites] S Afr J Surg. 1989 Jun;27(2):67-8 [2749413.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Surg Today. 1993;23(8):733-6 [8400678.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(3):303-11 [10526067.001]
  • [Cites] Surgery. 1992 May;111(5):489-94 [1317976.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):65-9; discussion 69-70 [7818000.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):786-95 [11088073.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):545-52 [7952456.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Chirurgie. 1998 Sep;123(4):363-7 [9828510.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2585-8 [10522046.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):602-6 [7684667.001]
  • [Cites] Br J Surg. 2000 Apr;87(4):434-8 [10759738.001]
  • [Cites] Am J Surg. 1967 Jan;113(1):77-84 [6016711.001]
  • [Cites] J Gastrointest Surg. 2004 Jul-Aug;8(5):532-8 [15239986.001]
  • [Cites] Ann Surg. 1996 May;223(5):506-11; discussion 511-2 [8651741.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):715-6 [10873008.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):359-64 [1998479.001]
  • [Cites] J Am Coll Surg. 2000 Jun;190(6):711-6 [10873007.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):190-6 [12555295.001]
  • [Cites] Br J Surg. 1988 Jul;75(7):719 [3416130.001]
  • [Cites] J Gastrointest Surg. 1998 Nov-Dec;2(6):509-16; discussion 516-7 [10457309.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):644-8; discussion 648-50 [10843359.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):493-501 [15120376.001]
  • (PMID = 16769536.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Liang H, Wang XN, Wang BG, Pan Y, Ding XW, Hao XS: [Management of nonfunctioning islet cell tumors of the pancreas]. Zhonghua Zhong Liu Za Zhi; 2007 Jun;29(6):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of nonfunctioning islet cell tumors of the pancreas].
  • OBJECTIVE: To analyze the clinical and pathological features in order to investigate appropriate way of diagnosis and treatment for non-functional islet cell tumors of the pancreas (NFICT).
  • Twenty-eight patients were diagnosed as having non-functional islet cell carcinomas of the pancreas (NFICC) and 15 patients benign islet cell tumors.
  • Multicemtric tumor were found in one patient.
  • The resectability and curative resection rate in 28 patients with nonfunctioning islet cell carcinomas of the pancreas was 78.6% and 60.7%, respectively.
  • None of the 15 patients with benign nonfunctioning islet cell tumor of the pancreas died of this disease.
  • While the overall cumulative 5- and 10-year survival rate in 28 patients with non-functional islet cell carcinomas of the pancreas was only 58.1% and 29.0%, respectively.
  • CONCLUSION: Nonfunctioning islet cell tumor of the pancreas is frequently found in young female.
  • [MeSH-major] Adenoma, Islet Cell / therapy. Carcinoma, Islet Cell / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974283.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


100. Krysiak R, Okopień B, Herman ZS: [Insulinoma]. Pol Merkur Lekarski; 2007 Jan;22(127):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Wyspiak wydzielajacy insuline.
  • Insulinoma is considered the most common endocrine tumour of the pancreas with an annual prevalence of 4 cases per million people.
  • Contrary to the other endocrine tumours of this organ, over 90% of the insulinomas are benign in nature.
  • Effective management requires directed biochemical testing, careful choice of preoperative imaging tests, and complete pancreatic exploration by an experienced endocrine surgeon utilising intraoperative ultrasound.
  • The only curative treatment for insulinoma is complete resection of the tumour.
  • [MeSH-major] Adenoma, Islet Cell / complications. Adenoma, Islet Cell / diagnosis. Insulinoma / complications. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endocrine Surgical Procedures / methods. Gastrinoma / complications. Gastrinoma / diagnosis. Gastrinoma / metabolism. Gastrinoma / surgery. Humans. Hypoglycemia / complications. Insulin / metabolism. Pancreatectomy / methods. Prognosis. Rare Diseases

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477096.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Insulin
  • [Number-of-references] 34
  •  go-up   go-down






Advertisement